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ABSTRACT
Evaluating Diagnostic and Treatment Modalities in the Management of Benign
Prostatic Hyperplasia in the Veterans Administration Population
Ancilla W. Fernandes

Benign prostatic hyperplasia (BPH), a common prostatic condition among aging males
significantly affects quality of life. Though clinical practice guidelines for BPH
management have been established, little research has been done to determine adherence
to such guidelines. To assess adherence to such guidelines, this study evaluated
diagnostic and treatment modalities in BPH management in the VA population (a
population with a high percentage of elderly males). A survey, containing simulated
BPH patient cases, was mailed to 292 VA urologists, of which 114 (39%) responded.
Urologists showed good adherence to the recommended diagnostic tests but preferences
varied for the optional tests depending upon severity of the patient case. Preferences for
treatment also showed considerable variation for the patient cases with different degrees
of symptom severity. The treatment failure rate for initiation therapy was determined to
be 42%. Study results need to be validated by tracking BPH patients using VA claims
data.
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CHAPTER ONE
INTRODUCTION

Benign prostatic hyperplasia (BPH), a non cancerous enlargement of the prostate
gland, occurs as part of the aging process in most men and results in obstruction of the
flow of urine from the bladder. Approximately 50 percent of men over the age of 60
have symptomatic BPH and by age 80, one in four men in the US will require treatment
for the relief of symptoms associated with BPH (Barry 1990,1991). In the US, more than
1 million men present annually with BPH (McIntyre & Grady, 1996). The high
prevalence of symptomatic benign prostatic hyperplasia (BPH) in elderly males is
evidenced by the fact that in 1989 transurethral prostactomy (TURP) was performed on
over a million males worldwide (Kirby & Christmas, 1993). Moreover, after cataract
extraction, TURP was the second most common operation performed on males over the
age of 65 years (Kirby & Christmas, 1993). According to 1993 estimates, due to
longevity of males in both the developing and the developed world, approximately 30
percent of males with BPH would require prostactomy unless equally effective
alternative treatments are developed (Kirby & Christmas, 1993). Autopsy studies have
indicated foci of histological BPH in the prostates of approximately 10 percent of males
aged 40 years and an increase in incidence with age upto almost 90 percent in males over
the age of 80 years (Berry, Coffey, Walsh & Ewing, 1984; Moore, 1943). Direct costs of
treatment for BPH range from $1,162 to $12,788 (Medicare) per person in the first year
depending upon the treatment strategy utilized (AHCPR, 1994). Also, depending upon
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the primary treatment, the costs for the second year range for $69 to $640. Thus, the
condition impacts a significant portion of the health care budget (Baum, 1997).
Accurate data on BPH as a primary cause of death are currently not available for
most countries in the world. The reported rate for the United States is 1.8 per 100,000
(AHCPR,1994). However, the lack of uniformity in criteria for attributing deaths to BPH
limits the usefulness of such figures. Although mortality from BPH is extremely rare, the
condition significantly impacts the quality of life in aging males by producing
bothersome urinary symptoms (Roehrborn, 1994). The patients seeking medical attention
do so due to the symptoms. The symptoms interrupt normal daytime activities and/or
sleep, create anxiety and reduce general perception of health. This reduces the quality of
life of the patient significantly (AHCPR, 1994). The symptoms of BPH are implications
of a complex interaction between the prostate and the bladder (McConnell, 1991). This
interaction gives rise to both irritative and obstructive symptoms. Obstructive symptoms
include decreased urinary stream force, sensation of incomplete emptying, difficulty
initiating the stream (hesitancy), and interruption of the stream (intermittency), while
irritative symptoms primarily include increased frequency, urgency, and nocturia.
Enlargement of the prostate causes increase in urethral resistance and this
decreases the bladder's ability to generate pressure in order to maintain flow (Roehrborn,
1994). Elevated detrusor pressures are achieved by hypertrophy, which is a
compensatory mechanism of the smooth muscle within the bladder wall. Although this
adaptive mechanism maintains relatively normal flow during the initial phases of the
disease, the detrusor smooth muscle is not necessarily functioning in an entirely normal
way. This obstruction-induced detrusor instability gives rise to the irritative symptoms of
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urinary frequency and urgency. Obstruction may also affect bladder sensory pathways
resulting in sensation of a full bladder, even at low volumes. Frequency and urgency
associated with urination may continue after bedtime, giving rise to nocturia. Many of
the symptoms of BPH may be aggravated because of age-related abnormalities in bladder
function (Roehrborn, 1994).
Little is known about the ultimate complications and morbidity associated with
untreated BPH, however sometimes it may lead to more serious symptomatic
complications (AHCPR,1994; Mebust, Howltgrewe, Cockett and Peters, 1989).
Obstruction of outlet may progress to development of acute urinary retention, i.e. the
sudden inability to urinate. Worldwide, 20 to 50 percent of patients are in urinary
retention when they undergo prostate surgery (AHCPR, 1994). Also, the likelihood that a
patient with a given symptom complex will go into complete urinary retention over a
given timespan is not well defined. Sometimes, uninhibited bladder contractions may
result in urinary incontinence. Patients with bladder outlet obstruction from any cause
may develop bladder calculi secondary to urinary stasis or a failure to pass stones formed
in the kidney through the lower urinary tract (Roehrborn, 1994). Urinary tract infection
can also cause complications. The probability of urinary tract infection increases as
residual urine increases usually, but this has not been observed with BPH. However, if
infection does occur, the patient may develop typical symptoms of dysuria, as well as
acute exacerbation of urinary frequency and urgency (Roehrborn, 1994). Some cases
may result in detrusor failure. However, the probability of this has not yet been well
established. In a minority of patients, bladder wall may be extensively damaged.
Patients may develop bladder diverticula which may impair bladder emptying. Thus,
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progression of symptoms in some patients may actually be due to progression of detrusor
dysfunction rather than due to progression of the anatomic obstruction. Uncommonly,
patients may show a significant decline in renal function (Mukamel, Nissenkorn, Boner,
& Servadio, 1979). Rarely, large veins in the prostate may rupture leading to gross
hematuria in patients with BPH. However, these are some of the less commonly
observed complications of the disease (Roehrborn, 1994).

Guidelines for Management of BPH
In 1994, recommendations for the diagnosis and treatment of BPH were
developed by a multidisciplinary panel of experts, under the sponsorship of the Agency
for Healthcare Research and Quality (AHRQ), (formerly the Agency for Health Care
Policy and Research-AHCPR)(AHCPR, 1994) (see Appendix Figure B). The AHRQ
(formerly AHCPR) was established to enhance the quality, appropriateness and
effectiveness of health care services and access to these services. It carries out its
mission by conducting and supporting general health services research, including medical
effectiveness research, facilitating development of clinical practice guidelines, and
disseminating research findings and guidelines to health care providers, policy makers
and the public. Guidelines assist practitioners and patients make appropriate decisions
for different clinical conditions. One of the major reasons for the development of
guidelines for BPH was the significant geographic variation in treatment patterns. This
was because of lack of sufficient understanding of etiology of the disease at that time and
the lack of long-term outcomes data regarding its natural history, treatment and indicators
to aid in the proper timing of treatment. The guidelines for BPH make specific
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recommendations to identify both the most effective methods for diagnosing BPH and the
most appropriate treatments for BPH based on patient preferences and clinical need.

Symptom Assessment and Diagnosis
Diagnosis commonly includes four steps: medical history, physical exam,
urinalysis and serum creatinine. Medical history is important to determine the presence
and severity of BPH. This is because most patients seeking treatment for BPH do so
because of bothersome symptoms. Symptoms of BPH are quantified using the AUA
symptom score, developed by the American Urological Association (Roberts, 1994). The
AUA symptom scoring system is an easy to use patient’s self-administered questionnaire
for measuring symptom level (see Appendix C). It consists of seven questions relating to
symptoms of BPH also called as prostatism. Each question on the AUA symptom index
can yield 0 to 5 points, producing a total symptom score with a range from 0 to 35. This
is used to categorize patients as having mild (a score of 0 to 7), moderate (a score of 8 to
19), and severe BPH (a score of 20 to 35). This tool has been tested, validated and found
to be most reliable instrument to quantify BPH related symptoms (Barry, Fowler,
O’Leary & Bruskewitz, 1992). Hence, it should be used in treatment planning and
periodically in follow-up, at least annually.
In addition to quantification of symptoms, an adequate medical history focusing
on the urinary tract, previous surgical procedures, general health issues, and fitness for
possible treatment procedures should also be obtained (Roehrborn, 1994). Specific areas
which need to be discussed include a history of hematuria, urinary tract infection,
diabetes, nervous system disease (Parkinson’s disease or stroke), urethral stricture
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disease, urinary retention and aggravation of symptoms by cold or sinus and current
medication information to determine if the patient is taking drugs that impair bladder
contractility (anticholinergics) or that increase outflow resistance (alpha
sympathomimetics).
Physical examination is in the form of a digital rectal examination (DRE) and a
focused neurological examination (Roehrborn, 1994). These are done primarily to detect
prostate or rectal malignancy, evaluate anal sphincter tone and rule out neurological
problems that may cause BPH like symptoms. Also, DRE establishes the approximate
size of the prostate gland, which is important for patients who choose invasive therapy
(McConnell, 1996). DRE provides a sufficiently accurate measurement in most cases.
However, the prostate size should not be considered in deciding whether active treatment
is required. This is because prostate size does not correlate with severity of symptoms,
degree of urodynamic obstruction or treatment outcomes (Roehrborn, Chinn & Fulgham,
1986; Simonsen, Moller-Madsen, & Dorflinger, 1987; Donkervoort, Zinner, & Sterling,
1975; Bissada, Finkbeiner, & Radman, 1976; Meyhoff, Ingemann, Nordling, & Hald,
1981).
Urinalysis is performed either by the dipstick method or by examining the spun
sediment (Roehrborn, 1994). This is done to rule out urinary tract infection and
haematuria. There is insufficient evidence about urinalysis being an effective screening
procedure (Preventive Task Force, 1989). This is because serious urinary tract disorders
are relatively uncommon, giving a low positive predictive value. However, in older men
with higher prevalence of these disorders the benefit of this innocuous test outweighs the
harm. Also, this test is necessary because a pathological finding will appropriately
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prompt tests such as renal imaging or endoscopy. If a dipstick test is utilized, a test that
includes fields for leukocyte esterase and nitric tests for the detection of bacteria and
urinary tract infection should be utilized (Roehrborn, 1994).
Serum creatinine is a tool used to measure renal dysfunction (Roehrborn, 1994).
There are many reasons for obtaining this test. First, to determine the percentage of BPH
patients who may have renal insufficiency. Renal insufficiency has been mentioned in
seven studies, which analyzed BPH treatments. In these, the percentage of patients with
renal insufficiency was between 0.3 to 30 percent, and the mean was 13.6 percent
(McConnell, Barry & Bruskewitz, 1994). The second important reason is that patients
with renal insufficiency have an increased risk for post-operative complications
(Roehrborn, 1994). The risk is 25 percent for patients with renal insufficiency compared
to 17 percent for patients without the condition (Mebust, Howltgrewe, & Crockett, 1989).
Also, patients with renal insufficiency have up to a six-fold increase in mortality rate
when surgically treated (Holtgrewe & Valk, 1962, Melchoir, Valk, Foret, & Mebust,
1974). An elevated serum creatinine guides the physician to recommend appropriate
imaging studies to evaluate the upper urinary tract in these patients (McConnell, 1996).
It is implicitly understood that if any other measure of renal function has been used, then
there is no need for laboratory investigation (Roehrborn, 1994).
In addition to the tests described above, there are some other tests which are used
for diagnosing BPH, but are not part of recommended guidelines and are left to the
discretion of the physician and patient. These include measurement of prostate specific
antigen (PSA) levels, uroflowmetry, pressure flow/max flow, measurement of post voidal
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residual volume, filling cystometry, urethrocystoscopy and imaging of urinary tract
(McConnell, 1996).
Measurement of prostate-specific antigen (PSA) is an optional test in AHRQ's
guidelines. This test in combination with a DRE, increases the detection rate of prostate
cancer over DRE alone (McConnell, 1996). However, making this test mandatory would
be controversial because (a) there is a significant overlap of PSA values between men
with BPH and men with organ defined cancer, (b) there is lack of consensus concerning
the optimal evaluation of minimally elevated PSA values, and (c) there is no evidence
that shows that PSA testing reduces mortality or morbidity of men with prostatic disease.
Also, comparison of serum PSA values of men with BPH and organ defined prostate
cancer has not shown statistical difference (Partin, Carter & Chan, 1990). Another
important factor is the value of early prostate cancer detection itself. No data is available
to establish that earlier diagnosis of cancer leads to decrease in morbidity and mortality
(McConnell, 1996).
Urologists typically use measurements of peak urinary flow rate. Uroflowmetry as
it is called, involves electronic recording of the urinary flow rate throughout the course of
micturition (McConnell, 1996). It is a non-invasive urodynamic test used to evaluate
patients presenting with symptoms of bladder outlet obstruction. An abnormally low rate
may be due to an obstruction (hyperplastic prostate, urethral stricture, meatal stenosis or
other obstruction) or due to weakness of the detrusor muscle.
Post voidal residual (PVR) volume, is the volume of fluid remaining in the
bladder immediately after completion of micturition (McConnell, 1996). Normal residual
volume ranges from 0.09 to 2.24 ml, with a mean of 0.53 ml (Hinnman & Cox, 1967).
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About 78 percent of normal men have residual volumes of less than 5 ml, and 100
percent have volumes of less than 12 ml (DiMare, Fish, Harper & Politano, 1963). PVR
measurement can be done both by non-invasive and invasive methods. The most
common method is urethral in-and-out catherization (McConnell, 1996). This method is
accurate if performed correctly but carries a small risk of discomfort, urethral injury,
urinary tract infection and transient bacteraemia. Ultrasonography is the non-invasive
method. Traditionally, urologists have assumed that increasing amounts of PVR denote
BPH progression and are thus an indication for surgery. However, data is lacking to
support the predictive value of PVR (McConnell, 1996).
Pressure flow studies should be proposed to patients if an invasive treatment is
considered (McConnell, 1996). Pressure flow studies differentiate between patients with
a low Qmax secondary to obstruction and those whose low Qmax is caused by a
decompensated or neurogenic bladder. They may also identify high-pressure obstruction
in symptomatic men with normal flow rates. Pressure flow studies should be performed
when distinction between urethral obstruction and impaired detrusor contractility will
affect therapeutic decisions. These studies have been developed to fill a diagnostic gap.
Another point to remember is that though pressure flow plots are generally recognized to
be more informative, interpretation of these plots has not been standardized (McConnell,
1996).
Filling cystometry is an invasive urodynamic study, which provides information
on bladder capacity, presence and threshold of uninhibited detrusor contractions (UDCs)
and bladder compliance (McConnell, 1996). UDCs are present in about 60 percent of
men with prostatism and correlate strongly with irritative voiding symptoms. Filling
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cystometry may be considered for men in urinary retention for those who cannot urinate
for a pressure flow study.
Urethrocystoscopy is a test recommended for men with prostatism who have a
history of haematuria, urethral stricture disease, bladder cancer, or prior lower urinary
tract surgery (McConnell, 1996). It helps the surgeon determine the most appropriate
technical approach for men with moderate to severe symptoms, who have chosen surgical
or other invasive therapy. Urethrocystoscopy provides visual documentation of the
appearance of the prostatic urethra and bladder in men with BPH. Historically, urologists
believed that the visual appearance of the lower urinary tract defines the severity of
disease or predicts the outcome of treatment. However, this procedure has been poorly
studied (McConnell, 1996). It is associated with certain benefits and harms. Potential
benefits include ability to demonstrate enlargement of prostate and visual obstruction of
the urethra and the bladder neck, identification of specific anatomical abnormalities that
alter clinical decision making, identification of bladder stones, trabeculation, cellules and
diverticular, measurement of PVR, and ruling out unrelated bladder and urethral
pathology. Potential harms are patient discomfort, anaesthetic or sedative risk, urinary
tract infection, bleeding and retention of urine. The probabilities of these harms is
uncertain and except for discomfort their occurrence is likely to be infrequent. However,
the endoscopic appearance of the bladder and prostate is often felt to be helpful in the
decision to treat i.e. it helps to select specific techniques, not determine the need for
treatment (McConnell, 1996).
Upper urinary tract imaging is another process not recommended unless the
patient also has one or more of the following: haematuria, urinary tract infection, renal
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insufficiency, history of urolithiasis, history of urinary tract surgery. It can be performed
either by intravenous urography (IVU) or by ultrasonography (McConnell, 1996). IVU is
associated with a 0.1 percent incidence of significant adverse events, whereas no direct
adverse events are known to be associated with ultrasonography.

Treatment of BPH
AHRQ guidelines recommend four treatment options for managing BPH:
watchful waiting, surgery, drug therapy and balloon dilation. Watchful waiting is used
mainly for patients with mild symptoms. A mild symptomatic patient (AUA score less
than 7) is advised to watch his symptoms and to return in one year for a repeat evaluation
unless a change directs him to return sooner. A man with moderate or severe symptoms
(AUA score greater than 8) is required to be counseled on all four treatment approaches.
The treatment decision is to be made by the patient with guidance from the health care
provider.
Surgical options include open surgery, transurethral resection of the prostate
(TURP), and transurethral incision of the prostate (TUIP). These are used most of the
times. Other surgical procedures which may be used but not recommended in the
guidelines are trans-vesical prostactomy, retropubic prostactomy, transurethral laser
incision of the prostate, transurethral microwave therapy and transurethral needle ablation
(Kirby & Christmas, 1993). Surgery is recommended for the following types of patients:
(a) those with refractory urinary retention who have shown failure with at least one
attempt at catheter removal, and (b) those who have shown to have recurrent urinary tract
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infections, recurrent gross haematuria, bladder stones or renal insufficiency clearly due to
BPH (McConnell, 1996).
Open surgery involves surgical removal of the inner portion of the prostate via a
suprapubic or retropubic incision in the lower abdominal area. The procedure is rarely
done through the perineum. Open prostactomy requires a longer hospital stay compared
to other surgical procedures (McConnell, 1996). Open surgery as a treatment for BPH is
now mainly indicated for large prostate weighing in excess of 80-100 grams. Only 5-10
percent fall into this category. It is also recommended for patients with osteoarthritis and
severe urethral stricture disease (Kirby & Christmas, 1993).
TURP is one of the most common procedures for benign prostates. It has
mortality rates of below 0.5 percent in the best medical centers (Holtgrewe, 1989). It is
the most common active treatment for symptomatic BPH and usually requires a hospital
stay (McConnell, 1996). The most common problem associated with TURP is
Transurethral (TUR) syndrome (Kirby & Christmas, 1993). The syndrome is
characterized by neurological symptoms such as confusion, coma, bradycardia, shortness
of breadth, cyanosis, oliguria and either an elevation or a decrease in blood pressure. This
is however uncommon with an incidence of less than 0.5 percent. It is more likely to
occur after lengthy resections.
TUIP is a procedure which decreases symptom scores equivalent to TURP but
with fewer complications. This procedure requires shorter hospitalization than TURP
and is associated with a lower incidence of bladder neck stenosis (Kirby & Christmas,
1993). Some of the other complications that may be associated with surgical prostactomy
are hemorrhage, incontinence, sexual dysfunction and urethral stricture. Because of the
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significant incidence of complication from prostactomy, a number of physical means of
relieving infravesical obstruction have been developed (Kirby & Christmas, 1993).
Balloon dilatation (dilation) is one such procedure.
There are two types of prostate balloon dilatation systems that are currently
available: one type utilizes a disposable endoscopic system to ensure correct positioning
of the balloon so that distal spincter is not dilated (Kirby & Christmas, 1993). The other
device employs a location balloon inflate in the bulbar urethra, and a collar on the
prostate balloon, which is palpable per rectum, to ensure that the device is correctly sited.
The results achieved with these devices have been somewhat mixed (Kirby & Christmas,
1993). Also, it is now beginning to emerge from a number of studies that balloon dilation
is likely to be effective in smaller prostates and in those patients who do not have severe
obstruction or prominent middle lobe enlargement. It is of no benefit in those patients
with either acute or chronic retention, in whom a TURP will yield far better results. Also
80 percent of cases require re-treatment within four years (Kirby & Christmas, 1993).
The non-invasive treatment approach for BPH is drug therapy. It primarily
involves use of alpha-1 adrenergic antagonists or 5-alpha reductase inhibitors (Kirby &
Christmas, 1993). Alpha-blockers act by inhibiting alpha-adrenergic mediated
contraction of prostatic smooth muscles (McConnell, 1996). The main disadvantage of
using these drugs is its effect on blood pressure. It requires caution when used in
hypertensive patients (Jardin, 1994). The most commonly used alpha-blockers are
terazosin, doxazosin and prazosin. 5-alpha reductase inhibitors act by blocking the
conversion of dihydroxytestosterone to testosterone. Finasteride is the most investigated
5-alpha reductase inhibitor at the present time. Early clinical studies suggested a
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reduction of prostate volume of 18 percent within three months using doses of 5mg/day,
as well as modest improvements in symptom score and uroflow (Stoner, 1992). In a sixmonth study the prostatic shrinkage was 28 percent (Stoner, 1990). The drug appears
well tolerated in all reported studies and the only adverse effects that occurred more
commonly were impotence, decreased libido and ejaculatory disturbances (Kirby &
Christmas, 1993). However, this has been observed in less than 4 percent of patients and
is reversible on stopping medications (Kirby & Christmas, 1993). A new medical agent
that has been introduced is tamsulosin, which is a prostate specific alpha-blocker, thus
associated with fewer hypotensive effects (Beduschi, Beduschi & Ricardo, 1998).
Another drug under clinical investigation is episteride, a 5-alpha reductase inhibitor
(McConnell, 1996).
In addition to all these approaches, there is an alternative therapy method that has
shown an increase in recent times. This includes use of phytotherapeutic preparations
like hemlock, ergot, strychnine, pumpkinseeds, rye pollen, hypoxis rooperus etc,
cholesterol lowering agents, amino acid complexes, and organic extracts (Fritzpatrick,
Dreikorn, Habib, Mebust, Perin, & Shultz, 1994). Their mechanisms of action have not
been documented. Also, a critical analysis of data available suggests that the effects of
phytotherapy and others are no better than those of placebo treatment (Dreikorn &
Schonhofer, 1995)

Adherence to Guidelines
Since the inception of the guidelines in 1994, two studies have been done to
evaluate practice trends of practitioners. A national survey of urologists in 1995,
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revealed practices consistent with the published guidelines in terms of examinations and
tests for men with suspected BPH (Barry, Fowler, Bin & Oesterling, 1997). The AUA
symptom index demonstrated routine use with a majority of the respondents and the use
of the optional tests varied. Also, alpha-blockers were reported to be prescribed four
times as often as finasteride and TURP was the most common surgical procedure.
Another study determined adherence rates to guidelines by reviewing inpatient records
(Hood, Burgess, Holtgrewe, Fleming, Mebust & Connolly, 1997). This study however,
also concluded that adherence to the guidelines recommendations is documented
infrequently in the medical records. The literature failed to identify any studies assessing
practice patterns of VA urologists for management of BPH, a gap that the proposed study
will aim to fill.

The Veterans Administration Program
In the U.S., the Veterans Administration (VA) program is designed to provide
health care services to retired, disabled, and otherwise deserving veterans of various U.S.
military conflicts. As of July 1, 1997, the VA population in the United States was
estimated at 25.6 million (VA Fact Sheet, 1998). Almost one-third of the nation's
population-- approximately 70 million persons who are veterans, dependents and
survivors of deceased veterans -- are potentially eligible for VA benefits and services.
VA's fiscal year 1998 appropriation was $40.4 billion of which $17.4 billion was for
medical programs. The Veterans Administration's health care system has grown from 54
hospitals in 1930 to 173 medical centers, with at least one in each of the 48 contiguous
states, Puerto Rico and District of Columbia (VA Fact Sheet, 1998). In recent years, VA
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has restructured its medical system into 22 integrated networks of care called Veterans
Integrated Services Network (VISN’s). See Appendix A for a listing of the twenty -two
VISNs. These are focused on pooling and aligning resources to best meet local needs in
the most cost-effective manner and provide greater access to care. The VA program
treats nearly a million patients annually in VA hospitals, 82,400 in nursing homes and
25,000 in domicilaries. VA's outpatient clinics register approximately 29.3 million visits
a year. An estimated 3 million individuals receive care annually (VA Fact Sheet, 1998).

Problem Statement
There are about 25 million male veterans living in the U. S. and its territories with
the average age being 57 years (VA fact sheet, 1998). Of these, more than 44 percent are
over the age of 60. Also, almost 18 percent of them are between 50 and 59 years old and
hence in the next decade upon reaching 60 would be at 50 percent risk of developing
BPH. With an increase in the life expectancy, the cases of BPH among this population is
expected to continue to increase. This probably will result in increased utilization of
healthcare resources and increased costs for managing this condition. With increasing
healthcare costs, sincere attempts must be made to ensure appropriate utilization of
diagnostic procedures and treatment alternatives in the management of BPH while
producing optimum outcomes in terms of relief of symptoms. Unnecessary procedures
and duplicative therapy if avoided can greatly reduce health care costs for the Veterans
Administration program. Since the inception of AHRQ guidelines in 1994, not much
research has been conducted to determine its implementation in actual practice. Also,
there has been no study conducted with regard to management of BPH in the VA
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population. Thus, an increasing elderly population, increasing prevalence of the disease,
and increasing health care costs in the VA program warrant greater attention to
appropriate management of BPH in this population.

Study Goals, Objectives and Research Questions
Even though clinical practice guidelines for the diagnosis and treatment of BPH
have been established, little research has been conducted to determine its effect on
urologists' practices in the VA population. Hence, the overall goal of this study is to
evaluate preferences of VA urologists in the use of diagnostic and treatment modalities in
the management of BPH. To accomplish this goal the following objectives and research
questions will be addressed:

Objective 1: To compare the preferences of VA urologists for diagnosing BPH with
established guidelines.
Research Question 1:
How do the preferences of the urologists practicing in the VA health care system
compare to established guidelines, for diagnostic evaluation of patients with benign
prostatic hyperplasia?
The available studies have assessed national urologists and patient data to
measure adherence to guidelines. However, VA urologists have not been studied. Thus
these urologists would be surveyed to determine similarities and differences in their
preferences of diagnostic tests with the guidelines. Also, effect of severity level on the
preference of these tests by respondents will be assessed.
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Objective 2: To compare the preferences of VA urologists for treating BPH with expert
opinion/established guidelines.
Research Question 2:
How do the preferences of VA urologists compare with the guidelines/ expert opinion
while selecting appropriate treatment option(s) for patients with benign prostatic
hyperplasia?
Here again there are no studies which have assessed management of symptoms
with preferences of urologist in the VA system. Also, the effect of severity levels on
treatment preferences has not been studied. The instrument used in this study includes
simulated patients with all three levels of severity (mild, moderate, severe). The
preferences of the respondents will be compared with the guidelines/ expert panel in an
attempt to address the above research question.

Objective 3: To determine the effect of demographic and practice characteristics on
preferences of VA urologists for diagnosing and treating BPH.
Research Question 3:
Do the demographic and practice characteristics of VA urologists have any effect on their
preferences for diagnostic and therapeutic management of patients with benign prostatic
hyperplasia?
This research question is proposed because the study with national urologists
indicated that older urologist ordered use of certain optional diagnostic tests more often
than younger urologists (Barry, Fowler, Bin & Oesterling, 1997). Also, younger
urologists preferred alpha-blockers compared to older urologists for management of BPH
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symptoms. Thus, it is necessary to determine if similar effects are observed among VA
urologists. Also, effects of other practice characteristics such as years of practice and
patient load on practice preferences will be assessed.

Objective 4: To assess the level of agreement among VA urologists on the use of
diagnostic tests and procedures for patients presenting with BPH symptoms.
Research Question 4:
Do VA urologists demonstrate agreement among themselves for diagnostic evaluation of
patients with BPH symptoms?
This research question is proposed because a study with international urologists
indicated disagreement for management of lower urinary tract symptoms (LUTS)
(Hansen & Zdanowski, 1997). The study concluded that this might result in increased
medical costs. Also, it demonstrated that LUTS from BPH seemed to be managed with
the poorest agreement. Exploring this research question will help identify if a similar
situation exists in the VA system for diagnostic evaluation of BPH.

Objective 5: To assess the level of agreement among VA urologists on the use of
treatment modalities for patients diagnosed with BPH.
Research Question 5:
Do VA urologists demonstrate agreement among themselves for selection of treatment
option for patients diagnosed with BPH?
Similar to the previous research question, this one intends to explore agreement
among VA urologists in their preferences for selection of treatment options for BPH.
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Objective 6: To determine the treatment failure rate for BPH in the VA population and
the types of treatment switches commonly made followed failed initiation therapy.
Research Question 6:
What is the treatment failure rate for initiation therapy among VA urologists and what are
the common treatment switches utilized?
Here an estimate of the failure rate of initial therapy for BPH among VA
urologists will be assessed. Also, the common switches among therapeutic options will
be obtained. This will help identify what initiation treatments result in the most switches,
and this when combined with treatment preferences will help justify if practice patterns
are appropriate.

Objective 7: To estimate the cost of diagnosing BPH in the VA population based on the
preferences of VA urologists.
Research Question 7:
What is the cost of diagnosing BPH patients in the VA system based on preferences of
VA urologists?
The intent is to determine average costs associated with the diagnostic evaluation
of BPH in the VA. Average charges for these tests will be used for this purpose. This
will help determine the burden or impact that the utilization of diagnostic tests has on the
VA health care system.
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Research Significance
The results of this study will help us better understand the preferences of
urologists for management of benign prostatic hyperplasia in the Veterans Administration
population. These preferences will be compared to the clinical guidelines available for
BPH. The practice guidelines aim to manage BPH in the most cost-effective manner with
optimum outcomes. This comparison of preferences of urologists with the guidelines
will help identify inappropriate patterns, if any. If inappropriate practice patterns are
identified, these can be further studied by the Veteran Administration Medical Centers
(VAMC). The VAMC's can then target urologists not conforming to practice guidelines,
with educational programs which increase awareness and improve compliance. Costs
associated with management of BPH depends on the severity of the disease and the
appropriate course of treatment. Increasing the awareness and use of appropriate practice
patterns may help curb unnecessary dollars spent on this condition. Thus, the VAMC's
will be able to reduce expenditures due to duplicative and or unnecessary processes.
Currently there are no economic studies that estimate the economic burden of BPH to the
US health care system (Kortt & Bootman, 1996). However, it has been estimated that
BPH, affects approximately 14 million older men and costs $4 billion annually
(McConnell, Barry, & Bruskewitz, 1994; Tsang & Garraway, 1994). Though we do not
aim to measure the economic burden of BPH to the US health care system, we will be
able to estimate burden to the VA system for diagnosis of BPH, based on preferences of
urologists. These results may not be generalizable to other healthcare settings. But the
lessons learned would definitely help management of BPH in other healthcare settings.
Also, the results of this exploratory study will serve as a springboard for similar studies
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that assess adherence to published guidelines for different types of disease conditions in
different healthcare settings.
In this chapter, the prevalence and burden of BPH, the different procedures
available for diagnosing and treating BPH and the need and significance of the study
were presented. The next chapter will present a review of the existing literature
associated with BPH management.
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CHAPTER TWO
LITERATURE REVIEW

This chapter summarizes the results of an extensive review of the available
literature with regards to published practice guidelines for the management of BPH,
comparison of diagnostic and treatment modalities available for BPH, use of simulated
patients in assessing practice patterns and studies involving management of BPH by
urologists and other health care providers.

Benign Prostatic Hyperplasia: Diagnostic and Treatment
Clinical Practice Guidelines
The AHRQ (formerly, AHCPR) BPH guideline panel worked for 3 years to
develop recommendations for practice (AHCPR, 1994). Literature associated with BPH
diagnosis and treatment was reviewed and critiqued by a panel of experts before making
the recommendations. Draft guidelines were then extensively peer reviewed by experts
and practitioners. Input was also obtained from men affected by BPH before the
publication of the final report. This report had two sections; diagnostic evaluation and
treatment recommendations.

Diagnostic Evaluation
The following procedures were recommended in the initial evaluation of all
patients presenting with prostatism, with the exception of testing of PSA (which is
optional) (AHCPR, 1994)
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-Detailed medical history focusing on the urinary tract, previous surgical procedures,
general health issues and fitness for possible surgical procedures, in order to detect other
causes of voiding dysfunction and comorbities that may complicate treatment. In case of
some patients a voiding diary is considered to be helpful to determine the frequency of
complaint.
-Physical examination which included a digital rectal examination and a focused
neurological examination.
-Urinalysis done by microscopic examination of sediment.
-Measurement of serum creatinine for assessment of renal function
Measurement of PSA is optional. This test increases the detection of prostate
cancer at an earlier stage. But it does not distinguish well between patients with
symptomatic BPH and cancer patients. Also, there was no evidence that it would
decrease mortality and morbidity associated from cancer
Symptom assessment- Symptoms are to be quantified by means of a self-administered
AUA symptom index. It has 7 questions relative to symptom of BPH or prostatism. In
this scoring system, symptoms are classified as mild (0 to 7), moderate (8 to 19), or
severe (20 to 35). This index is to be used in assessing degree of bothersomeness,
treatment planning and follow-up. However, AUA symptom index is not meant to be the
sole means of diagnosing, BPH, because the symptoms are not specific for BPH.
Additional diagnostics tests- Several additional diagnostic tests are available to assess
patients with BPH. However, due to insufficient data, their value in diagnosing BPH and
predicting the results of treatment were not confirmed. Moreover, the differences
between normal and abnormal values were uncertain. Results of these tests could not
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define BPH and their use was not considered as mandatory. However, they could be
useful for patients with uncertain diagnosis. The tests that are considered optional after
initial evaluation are: a) Uroflowmetry, helps identify those, whose maximum flow rate is
not diminished and are less likely to benefit from therapy. b) PVR, is poorly reproducible
for a given patient. However, it could be used during the course of the disease to detect
worsening of bladder function. c) Pressure flow studies, are helpful in patients with
previous bladder dysfunction as the cause of lower urinary tract symptoms. However,
their usefulness in work-up of patient is thought to be questionable. In addition to these
optional tests, there are tests which are not recommended in routine cases. These include
imaging of upper urinary tract, filling cystometry, and urethrocystoscopy, particularly
when symptoms are associated with hematuria and/or irritation.

Treatment Recommendations
The AHRQ- BPH guideline panel made the following recommendations for
treatment of patients with BPH (McDonnell, Barry, Bruskewitz et al, 1994):
Patients with mild symptoms – these included patients with an AUA score of less than 7.
The strategy for these patients is watchful waiting. The patient is to be monitored,
usually annually and instructed on behavioral techniques to reduce symptoms, such as
limiting fluid intake and avoiding decongestants. If patient’s symptoms progress to
moderate and severe levels then symptoms have to be reassessed and other treatment
options be offered to him.
Patients with moderate and severe symptoms - these patients have to be provided with
information about benefits and harms of watchful waiting, alpha-blocker therapy,
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finasteride therapy and surgery. The guidelines require the patient to be informed of all
available treatment options applicable to his condition with related risks and benefits.
This information is to be given in an unbiased format with probabilities of benefits and
uncertainties associated with the probabilities. The physician is required to act as a
communicator and present outcomes data to let patient decide the best treatment.
Depending on the treatment patients select, appropriate follow-up needs to be
determined. These guidelines are summarized in Appendix B.
The key decisions in the evaluative process involve assessment of patient
symptoms. Following a detailed focussed history, physical examination and laboratory
evaluation to identify other causes of urinary problems and comorbities that may
complicate treatment, the guidelines suggest quantification of symptoms by selfadministration of the AUA symptom index. Men with symptoms of 0 to 7 are to be
allocated to watchful waiting with periodic assessment. Men with moderate to severe
symptoms i.e. scores of 8 or higher are to be directed to optional diagnostic tests,
treatment or watchful waiting based on clinical judgement of patient and physician.

Comparison of Diagnostic and Treatment Modalities:
Among the different BPH diagnostic tests, the ones that have been most studied
and presented in the literature include the assessment of symptoms by the use of the AUA
symptom index (AUA- si) and the prostate specific antigen (PSA) levels. This maybe
due to the fact that both these diagnostic measures do not differentiate very well patients
with BPH from those with other lower urinary tract symptoms (for AUA symptom score)
and from prostate cancer (for PSA levels). Chancellor, Rivas et al (1994) carried out a
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study to compare the specificity of the American Urological association (AUA) symptom
index for BPH versus other urodynamically verified micturitional dysfunction in men.
Results indicated that the AUA symptom index does not specifically identify BPH or
bladder outlet obstruction. The scores were similar between men with voiding symptoms
secondary to bladder dysfunction and bladder outlet obstruction. Another study
administered this index to women and found that women with voiding dysfunction gave
similar scores (Chancellor & Rivas, 1993). However, it has been emphasized that the
purpose of the AUA symptom index is not to distinguish patients with BPH but to
quantify the symptoms. Also, validation studies have been done which show that the
symptom index captures clinically important changes in patients’ condition (Barry,
O'Leary, Bruskewitz, Howltegrewe et al, 1992).
A test that measures prostate specific antigen levels also has been extensively
studied. This test provides insufficient discrimination between BPH and organ confined
prostate cancer (Wolff, Boeckmann, Borchers, Handt, Reineke & Jaske, 1996).
However, recent studies have shown that the ratio of the free prostate specific antigen to
the total PSA in serum, calculated as a percent of free PSA is lower in patients with
prostate carcinoma than in patients with benign prostatic hyperplasia (Meyer, Jung, Lein,
Rudolph, Schnorr & Loening, 1997). Thus, this parameter is of help and facilitates
discrimination between the two groups of patients.
Among the treatment modalities, watchful waiting and transurethral resection of
the prostate (TURP) were options most commonly used. Until the late 1980s, TURP was
the standard treatment for BPH when watchful waiting failed (Bruskewitz, 1992). Inspite
of the fact that surgery provided far greater improvement in symptoms and urodynamic
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parameters than pharmacotherapy, pharmacotherapy for BPH began to be reported in
medical literature between 1988 and 1990 (Guess, Jacobsen & Girman 1995; Lowe,
McDaniel, Chmiel & Hillman, 1995). This is due to the morbidity associated with
surgery (Eri & Tveter, 1997). Surgery involves loss of work time, need for
hospitalization, performance of invasive procedures with well-described set of
complications.
Drug therapy for BPH involves two classes of drugs, alpha-blockers and 5 alpha
reductase inhibitors. Alpha-blockers include prazosin, terazosin, doxazosin and
tamsulosin, whereas 5 alpha reductase inhibitors include finasteride. Both these classes
of drugs are well-tolerated and effective in patients with BPH (Eri & Tveter, 1995). The
various alpha-blockers are similar in efficacy and adverse effect profiles and act by
reducing the smooth muscle tone of the prostate and the bladder neck. Finasteride on the
other hand shrinks the prostate by blocking conversion of dihydrotestosterone to
testosterone. A meta-analysis of placebo controlled studies with alpha-blockers showed
that these drugs decrease symptom score and improve urinary flow rate (Eri & Tveter,
1995). Their effect was usually seen within the first two weeks and reached maximum
clinical effect after 4 to 8 weeks. Finasteride, on the other hand is known to act slowly.
Its effect is seen only after 6 months of therapy. But long-term results have shown that
its efficacy increases over time. Studies have been reported comparing these two classes
of drug therapies. In a Veterans Administration Cooperative study, terazosin, finasteride
and a combination of the two were compared (Lepor, Wilford, Barry, Brawker, Dixon,
Gormley, Haakenson, Machi, Narayan & Padley, 1996). The investigators concluded
that terazosin was effective whereas finasteride was not. Also, the combination was no
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more effective than terazosin. This was because finasteride performs best in men with
large prostates (at least 40 grams) while the average size of prostate in this study was 37
grams. Efficacy of finasteride was confirmed in a meta-analysis of six studies using
finasteride (Boyle, Gould, & Roehrborn, 1996). The alpha-blockers are associated with
adverse effects of dizziness, orthostatic hypotension and asthenia in 5 to 29 percent of the
patients. However, tamsulosin, an alpha1A blocker, is prostate selective giving a more
prostate specific action and fewer adverse effects (Eri & Tveter, 1995). Finasteride on
the other hand, is known to impair erectile function in 2 to 7 percent of patients, but this
is reversible on discontinuation of therapy.
Surgical management of benign prostatic hyperplasia has also gone through an
emerging phase (Jepsen & Bruskewitz, 1998). Open prostatectomy is the oldest and most
invasive procedure but it is the most efficient in relieving symptoms and improving flow.
It is recommended in patients with prostates greater than 50 grams. Compared to
transurethral resection of prostate (TURP) it has lower peri-operative mortality.
However, TURP has become the gold standard for treatment of BPH because the
procedure is less invasive, less expensive, and associated with less morbidity. A variety
of less invasive procedures have been introduced and these well-established procedures
are being reassessed. Some of the newer procedures include transurethral incision of the
prostate (TUIP), visually assisted laser prostactomy (VLAP), interstitial coagulation
(ILC), transurethral microwave thermotherapy (TUMT) and transurethral needle ablation
(TUNA). Transurethral electrovaporization of the prostate (TVP), another method is a
modification of TURP. TURP is an inpatient procedure performed under general or
spinal anesthesia. In a trial of watchful waiting versus surgery, TURP showed less
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morbidity than previous studies (Wassan, Reda, Bruskewitz, Elinson, Kelley &
Henderson, 1995). Also, it indicated that compared to watchful waiting it was not
associated with increased impotence or urinary incontinence. However, it does portray
the risk of reduced or absent ejaculation and should not be performed in men who want to
stay fertile. TVP is a modification of TURP using a roller-ball electrode with high
current that vaporizes the tissue. Results of this procedure are comparable to TURP.
Also, it is known to prevent TURP syndrome. In addition to this, it appears to be more
effective in reducing the number of catherizations and hospitalizations, proving to be
more cost effective (Thomas, Coraby, Hammadeh, Philp & Mathew, 1997).
Among the other surgical methods, TUIP is more than 30 years old, is welldocumented and a safe procedure that is less expensive than other surgical procedures
(Jepsen & Bruskewitz, 1998). It can be performed on an out-patient basis and is
indicated in men with prostates less than 50 or 60 grams. It causes less morbidity than
TURP and its re-treatment rate is approximately equal to that noted with TURP. VLAP
and ILC are techniques which use laser therapy. Laser therapy can be divided into
procedures which result in either coagulation or vaporization of tissue. Both VLAP and
ILC involve coagulation. ILC technique produces less improvement than VLAP. VLAP
is a shorter procedure, produces lower morbidity, and thus appears to be viable and safe
alternative to standard TURP. However, a study showed that it does not result in as
complete a removal of prostatic tissue as TURP (Cowles, Kabalin, Childs, Lepor, Dixon,
Stein & Zabbo, 1995).
TUMT with urethral cooling, another method causes a delayed interstitial ablation
of the prostate. A study comparing the outcomes of TUMT with TURP concluded that
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inspite of improvement in symptoms it did not alleviate obstruction in patients with BPH
(Bell, Ward & Watson, 1997). But it is minimally invasive with no absolute
contraindications. The cost is difficult to estimate due to lack of long term data. TUNA,
the last of mentioned methods, utilizes low-level energy by radiofrequency (Jepsen &
Bruskewitz, 1998). The improvements in symptoms are less compared to TURP, but
better when compared with TUMT. Treatment failure rates of TUNA are comparable to
TUMT. A clinical and urodynamic evaluation concluded that it is a safe and effective
procedure when performed as an outpatient procedure. However, long term costs and
outcomes have yet to be assessed (Campo, Bergamaschi, Corrada & Ordesi, 1997).
The cost of TURP in the US ranged from $6000 to $7000 per patient in 1993 (Eri
& Tveter, 1997). When we compare this with drug therapy, annual cost of finasteride
was $600 and alpha-blockers ranged from $300 to $400, both in 1993 dollars. Cost of
TURP corresponds to approximately 8 years treatment with finasteride or 13 years
treatment with alpha blockers provided the annual follow-up is around $200 per patient
and there is no follow up after surgery. Thus, it is important to decide what therapy
should be used for a particular patient. An economic model compared the costs of
treatment for a period of two years with finasteride, terazosin and TURP with men who
had at least moderate symptoms (Lowe, McDaniel, Chmeil & Hillman, 1995). Results
indicated that surgery had the highest probability of success but was the most expensive
and resulted in maximum loss of activity days. This study concluded that
pharmacotherapy was less expensive over the initial two years of therapy when used as a
primary intervention over surgery. Another pharmacoeconomic analysis compared
finasteride with doxazosin, prazosin and terazosin (Cockrum, Finder, Ries & Potyk,
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1997). This assessed economic outcomes for a period of three years. It concluded that
alpha-blockers were more cost effective than finasteride and of the three alpha-blockers
included in the study, prazosin was most cost-effective followed by terazosin and
doxazosin. Some other studies which have looked at economics of BPH treatment
options include cost-effectiveness between finasteride to TURP and watchful waiting,
comparing enucleation (prostactomy) with TURP using cost-utility analysis, assessing
cost-of-illness of BPH and measurements of lifetime costs for synthetic cohorts of BPH
patients (Baladi, Menon & Otten, 1996; Woodward, Boyarsky & Barnett; 1983,
Drummond, McGuire & Black NA, 1993; Chiriko & Sanford, 1996). The first study
indicated that when duration of therapy was 3 years or less, finasteride was the preferred
option for patients with moderate symptoms. However, when the therapy was for more
than 4 years, finasteride was a weaker option for patients with severe symptoms. It
concluded that finasteride can improve quality of life for patients with moderate
symptoms (finasteride therapy for more than 4 years) and patients with severe symptoms
(finasteride therapy for less than 3 years) but would cost approximately $ 97,000
(Canadian dollars) per incremental QALY (quality adjusted life years). The second study
concluded that enucleation was more cost-effective than TURP. In 1990, the economic
burden of BPH was estimated in the United Kingdom, and was found to be between 62 to
91 million pounds. The study that assessed synthetic cohorts (groups) reported that cost
of each type of BPH therapy depended on age of the patient. It indicated that surgical
intervention had a cost advantage at younger patient ages, while drug management had
cost advantage at older ages.
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Use of Simulated Patients in Assessing Practice Patterns
Measurement of practitioners’ performance has been stimulated by two needs: 1)
to ensure quality of care; and 2) to examine effectiveness of educational programs
(Norman, Neufiled, Walsh, Woodward & McConver, 1985). The most common method
to measure practitioner performance is by retrospective audit of medical charts. But this
suffers from the possibility of having patient charts with missing critical information. An
alternative approach to assess quality of care and performance is using standardized or
simulated patients. A simulated patient in literature is "a person who has been trained to
simulate all aspects of a disease". (Barrows, 1971). The term standardized is used for
both healthy individuals and patients who are trained to present clinical problems
consistently and repeatedly. This method has been used for educational purpose in
evaluation of undergraduates and residents (Norman, Tugwell & Feightner, 1982). The
validity of using simulated patients for this purpose has been established. This
methodology also demonstrated feasibility when used to assess physicians’ performance
and quality of care (Norman, Neufiled, Walsh, Woodward & McConver, 1985). Rethens
and Boven (1987) showed that simulated patients could produce reliable and valid data
about the performance of doctors in actual practice. They conducted a study in which
they used three simulated patients with symptomatic urinary tract infections to assess
quality of care provided by 48 general practitioners. This study used patient simulation
in two ways a) having simulated patients visiting the practitioners; and b) sending a
written patient case to the practitioners. The overall score for both the methods did not
show any substantial differences. This study encouraged the use of simulated patient
method as a basis for assessing the actual performance patterns of practitioners. Another
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study which utilized simulated patients was done to measure level of agreement among
randomly selected international urologists in the management of men with lower urinary
tract symptoms (LUTS) (Hansen & Zdanowski, 1997). This study utilized computer
simulation to provide unbiased format of simulated cases to individual urologists. It
indicated considerable disagreement among urologists about management of men with
LUTS, which included both the choices of diagnostic tests and the criteria for offering
therapy to patients. This study concluded that this disagreement might result in
unnecessary medical costs for these patients.

Previous Studies Assessing Practice Patterns in the Management of BPH
The prevalence of BPH has been increasing due to the aging population.
Approximately, 50 percent of men over the age of 60 have symptomatic BPH and by age
80, one in four men in the US will require treatment for the relief of symptoms associated
with BPH (Barry 1990,1991). Traditionally specialists have referred patients with BPH
to urologists for diagnosis and management. However, there has been an increasing trend
to involve primary care practitioners in the diagnosis and management of this disorder.
This can be through the concept of shared care. This enables medical services to deal
with increasing numbers of men seeking advice for BPH and also reduces the wait for
patients who need assessment by urologists (Morris, Pogson & Shearer, 1995). Thus,
studies on the management of BPH have looked at both primary care practitioners and
urologists. The literature yielded two studies that have assessed practice trends of primary
care practitioners. One was conducted among delegates attending scientific meetings on
prostate disease (Fawzy, Fontenot, Guthrie, & Baudier, 1997). Results indicated that
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about one-third of the respondents used AUA symptom index for diagnosing BPH and
long acting alpha-blockers was the most preferred mode of treatment. However, these
physicians included a cohort with a particular interest in prostate disorders and the results
are not representative for all primary care practitioners. The second study, however was
a mail survey of primary care practitioners in Brooklyn, New York (Plawker, Fleisher,
Nitti & Macchia, 1996). This study showed that 66.5 percent of primary care
practitioners were not familiar with the AUA symptom index. Also, less than 50 percent
attempted pharmacotherapy with finasteride or terazosin or both and about 15 percent of
these were not aware of the mechanisms of action of these drugs. This study concluded
that primary care practitioners needed further education in regard to use of diagnostics
tests and pharmacotherapy for men with voiding dysfunction.
Additionally, studies have been conducted to evaluate the practice trends of
urologists. A nationwide survey of urologists on management of BPH was conducted by
Barry et al (Barry, Fowler, Bin & Oesterling, 1997). This study indicated that older
urologists tend to perform TURP more often than younger urologists. Also, they tend to
obtain diagnostic tests not recommended by the guidelines more often than younger
urologists do. Younger urologists prescribed alpha-blockers more often. In general,
alpha-blockers were reported to be prescribed more than 4 times as often as finasteride.
This study concluded that respondents were fairly consistent with published BPH practice
guidelines. When a comparison was made between practices of primary care
practitioners and urologists (McNaughton, Barry, Roberts, Oesterling & Fowler, 1997),
diagnostic evaluations of primary care practitioners varied from the recommendations of
national guidelines and urologists practices. This study also showed that urologists'
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diagnostic evaluation would also deviate at times from guidelines. Another observation
was that both classes of practitioners used alpha-blockers more often that finasteride.
However, increasing awareness and better compliance with guidelines by primary
practitioners was stressed even in this study.
A gallop organization in Princeton was commissioned to assess practice patterns
of urologists in 1992 (Gee, Holtgrewe, Albertsen, Liwin, Albertsen, Manyak, O'Leary, &
Painter, 1995). This showed that 99 percent of the respondents were aware of and used
the AUA symptom index, and that 21 percent of the respondents had altered their
strategies of diagnosis and management because of this instrument. This study concluded
that therapeutic recommendations of respondents based on AUA symptom index
paralleled the practice guidelines. When patient records with principle diagnosis of BPH
were extracted from a random four-state sample to measure adherence to practice
guidelines, different results were observed (Hood, Burgess, Holtegrewe, Fleming, Mebust
& Connolly, 1997). These were patients who had undergone TURP, but their records did
not show adequate peri-operative evaluation of patients undergoing TURP. The study
concluded that guideline recommendations are documented infrequently in medical
records.
The various studies, which have assessed compliance with guidelines,
demonstrate inconsistency in results and conclusions made. Also, all these studies suffer
from the major drawback of recall bias since the survey instruments used intended the
respondent to report about his/her practice over several months. Another point to
consider is that the guidelines recommend different therapy for patients with different
levels of severity. However, none of the above studies looked at the practice patterns
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based on severity of symptoms. Hence, one cannot conclude if the practitioners were
consistent with guidelines based on different levels of severity. In addition to all these
factors, these studies have assessed practitioners in general all over the country.
However, none of them have assessed practice patterns of urologists serving the VA
population. These urologists form a different cohort practicing in a different healthcare
structure. Thus, our study aims to assess practice patterns of this cohort of urologists.
Additionally, to exclude the effect of recall bias simulated patient cases with different
severity levels will be employed for this study. The validity of using written simulated
patients has been demonstrated in literature (Rethens & Bovens, 1987). This would not
only help identify compliance of therapeutic recommendations for patients with different
severity levels, but also help detect differences, if any, in management of patients with
different severity levels. Also, important factor is by using simulated patient cases, all
respondents would have the same case and thus we would enable measurement of the
degree of agreement among practitioners.
There have been new and emerging methods for management of symptoms of the
disease. However, these were not included in the original guidelines due to inadequacy
of data. Hence, these new techniques have not been studied extensively in literature with
regards to urologists’ practice. This study aims to include all such modalities which have
shown some degree of effectiveness and which the expert panel used for identifying the
patient cases considered to be necessary.
Thus, this chapter presented a review of the literature relevant to the problem
being investigated in this study. It included the published guidelines for management of
BPH, comparison of diagnostic and treatment modalities available for BPH, use of
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simulated patients in assessing practice patterns, and studies involving management of
BPH by urologists and other health care practitioners. The next chapter will discuss the
methodology employed to accomplish goals and objectives of this study.

.
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CHAPTER THREE
RESEARCH METHODOLGY

The intent of this study was to assess VA urologists’ preferences in the
management of benign prostatic hyperplasia with regards to severity of the symptoms,
demographics and practice characteristics. Specific objectives were (i) to compare the
preferences of VA urologists for diagnosing BPH with established guidelines, (ii) to
compare the preferences of VA urologists for treating BPH with expert
opinion/established guidelines, (iii) to determine the effect of demographic and practice
characteristics on preferences of VA urologists for diagnosing and treating BPH, (iv) to
assess the level of agreement among VA urologists on the use of diagnostic tests and
procedures for patients presenting with BPH symptoms, (v) to assess the level of
agreement among VA urologists on the use of treatment modalities for patients diagnosed
with BPH, (vi) to determine the treatment failure rate for BPH in the VA population and
the types of treatment switches commonly made followed failed initiation therapy, and
(vii) to estimate the cost of diagnosing BPH in the VA population based on preferences
of urologists.
This chapter presents methods employed to achieve the preceding objectives
including study population, sampling, instrument content and development, survey
implementation, and data analysis.
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Study Population
The population of interest in this study was, urologists practicing in the Veterans
Administration Medical Centers (approximately 173) all over the United States.
However, working within budget and time constraints made it impossible to reach out to
every eligible person. Consequently the study population was defined as urologists
practicing in those VAMC’s whose center was listed on the VA web-site. The web-site
had a listing of 149 such centers.

Sampling
Due to difficulty in observing the entire study population, a sample, which is a
portion representative of the study population, was drawn for this study. The logic
behind sampling draws on the ability of making inferences about the population based on
the data collected from the sample. This section will deal with the issue of sample
selection and screening.
Although the population of the study was clearly defined, an appropriate sampling
frame consisting of all eligible urologists from whom the actual sample was to be drawn
(exclusive list of urologists practicing in the VAMC’s) was not readily available. The
use of telephone directory as a sampling frame was ruled out due to the potential bias that
could be introduced by excluding those urologists whose numbers are not listed.
Assuming that each VAMC has 2-4 urologists would result in a population ranging from
248 to 596. Due to the small population size, it was decided to include as many
urologists as possible in the study. This could help enhance response rate and make the
results more representative of the population selected. Also, personalizing the cover
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letter to be sent with the survey would also serve to enhance the response rate. Efforts
were made to get a directory exclusive to the VA, which had telephone numbers and
other details of healthcare professionals practicing in the VA. However, since this
directory did not have the urologist specifically listed, it could not be used.
Hence, a different approach was taken to obtain names of urologists. Telephone
numbers of all the VAMC’s listed on the web-site were first identified. Each VAMC was
then called and the Department of Urology was requested. The secretary or nurses in
these departments were the contact persons. They were given information about the
survey that was to be conducted among urologists as part of this study, for which names
of urologists practicing at their center would be required. The mailing addresses of these
centers were obtained from the VA web-site that had links to each center’s homepage.
Some of the centers did not list their phone numbers but had a fax number. Also, some of
the nurses/ secretaries refused to disclose the names of the urologists, citing reasons of
confidentiality. Some of the centers could not be reached because of busy telephone
lines. Two additional attempts were made to reach these centers by telephone. Those
that could not be reached after three calls were not included. Some of the centers did not
have a practicing urologist since the center was small or because there was another center
in the city with a full-capacity urology department. Another important observation was
that in some states, the same urologists practiced at multiple centers. For two of the
centers, the contact persons refused to divulge the names of the urologist but did provide
the number of urologists practicing. Completion of the telephone calls to obtain names of
urologists resulted in a list of 233 urologists practicing at 88 centers of the 149 centers
identified. To increase the study sample size, a single survey was sent to chief urologists
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at the remaining 61 centers. Thus, the sample selection procedure resulted in 233 usable
names from 88 centers, and 61 chief urologists (unidentified by names) from 61 centers,
resulting in a total sample of 294 urologists.

Instrument Content and Development
A self-administered mail survey was used for this study. Mail surveys offer many
advantages such as ability to collect data from a larger geographical area at a relatively
low cost, greater versatility, the absence of interviewer bias and successful use of a small
staff. For the respondents, it offers the flexibility of replying at their convenience and
offers respondent anonymity.
In developing the survey instrument, considerable attention should be given to the
kind of information needed to measure both the independent and dependent variables of
interest, length of questionnaire, cost, comprehension level of prospective respondents,
complexity of the questionnaire and the time required to complete it (Dillon, 1978). All
these factors collectively can have a significant impact on the kind of data collected and
the response rate.
This survey intended to measure preferences of urologists in diagnosing and
treating BPH. Consensus was reached among the researchers that the best way to do so
would be to provide simulated patient cases in the survey. To do so, a search of the
literature was conducted to determine if there were any standard patient cases with BPH.
The book selected was Applied Therapeutics: The Clinical Use of Drugs (6th edition) by
Young and Koda Kimble (1995). This book is used to educate clinical pharmacists about
management of different conditions, BPH being one of them. The patient case obtained
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from this source depicted the symptoms, which a typical BPH patient presents with, some
laboratory tests used to diagnose the case and the treatment options available to control
the symptoms. It provided a detailed description of all the tests and treatment options
suitable. This case was taken as a template and modified to obtain the required cases for
the survey instrument. The survey instrument had four sections. Section one was
designed to measure association of the use of diagnostic tests with bothersome symptom
level. It was decided to include three cases with different levels (low, medium and high)
of bothersome symptoms. Expert opinion from urologists practicing at West Virginia
University, School of Medicine was utilized for this purpose. A list of symptoms to be
included for each patient case with different levels of bothersome symptoms was
obtained. This procedure resulted in three patient cases with different bothersome
symptom levels, typical of BPH. The response options included all the diagnostic tests,
which are part of AHCPR’s guidelines and some others that were cited in the literature.
To avoid respondent bias, the cases were arranged randomly such that case 1 depicted
medium symptoms, case 2 depicted low symptoms and case 3 depicted high bothersome
symptoms.
Section two was designed to include patient cases for the treatment section of the
survey. For this, symptoms similar to the diagnosis (Section I) were taken. This was
supplemented with information of results of certain diagnostic tests and laboratory
values. The laboratory values and other information was utilized such that it would
distinguish between patients with mild, moderate and severe symptoms (the typical
classification system used for BPH). The information about results of diagnostic tests
and laboratory values was obtained from expert opinion. This resulted in three patient
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cases- mild, moderate, and severe. Urologists were asked to recommend the best
treatment option(s) for each case from a list of commonly recommended and less
frequently used treatment alternatives. To avoid bias, these three cases were also
arranged randomly and not in increasing order of severity. Thus, case 4 was severe, case
5 was moderate and case 6 was mild.
One of the objectives of the study was to estimate the initial treatment failure rate
and common switches utilized. Thus, Section three contained a list of possible treatment
switches that was obtained with help from experts. This section was different from the
previous two in that it did not involve preferences for simulated patients but, sought
information about practice characteristics in real settings. The respondents were required
to recall the last five BPH patients they had treated. The number was limited to five to
avoid recall bias and failure of recall. The respondents were inquired as to the number of
patients among these last five, who had to be switched to other treatment options due to
failure of initiation therapy. It also sought information about the type of switch, if any.
Section four of the instrument pertained to respondents demographic and practice
characteristics. These included variables such as age, gender, years of practice, number
of new BPH patients seen per month, presence or absence of a formulary, the different
BPH drugs available on the formulary, and number of urologists at practicing center.
These variables were selected to determine if there was some association between them
and the diagnostic tests used and the treatment options selected. Demographic factors
were measured using either a dichotomous scale or an interval scale. Open-ended
questions were primarily used to obtain information about practice characteristics except
for the question associated with the drug formulary.
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Instrument Pretest
The survey instrument was pre-tested to assess clarity, readability, face validity,
reliability and time for completion. For the pretest, the preliminary questionnaire was
administered to a convenient sample of eight, resident urologists at West Virginia
University, School of Medicine. Of this four questionnaires were retrieved, to yield a
response rate of 50 percent. In addition to assessing the clarity and readability of the
instrument, the residents were asked to classify the patient cases in section two (selection
of treatment option) as mild, moderate and severe. The result of this is summarized in
table 3.1. All four residents classified the moderate and the severe case correctly. The
mild case was identified correctly by 3 of the 4 residents, 1 classified the case as
moderate. Thus, there was 100 percent agreement for the moderate and severe case and
75 percent agreement for the mild case. A kappa statistic was calculated to measure this
agreement using the method for multiple raters (Woolson, 1987). This gave a value of
0.745 with standard deviation of 0.089. The Z value was 8.37, thus the kappa statistic
was significant. A kappa of 0.745 is interpreted to demonstrate substantial agreement
among raters (Landis and Koch, 1977). Thus, validity of the cases was established with
regards to patient severity.

Instrument Validity
The clarity and face validity of the instrument was assessed using the pilot survey
results. The face validity of the instrument was also assessed by the experts. Experts in
health services research from the Department of Pharmaceutical Systems and Policy, and
urologists from the School of Medicine reviewed the instrument to determine its clarity
and appropriateness. Content validity is defined as “the extent to which test exercises
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Table 3.1: Classification of patient cases in section two of survey.
Patient case

Mild

Moderate

Severe

Percent classified correctly

Case 4*

-

-

4

100.00

Case 5*

-

4

-

100.00

Case 6*

3

1

-

75.00

*Patient # 4: A.D., a 75-year-old African-American male comes with the problem of urinary incontinence.
He also gives a history of difficulty initiating urination, midstream stoppage and terminal dribbling. Rectal
examination reveals an enlarged prostate of 50-55 gms. A.D. gives a history of nocturia approximately 4-5
times a night, daytime urinary frequency of 8-10 times a day and he reports of blood in urine. Laboratory
findings are as follows: PSA -4.1, AUA ss -28, serum creatinine -1.2, residual volume -300ml, flow rate 7ml/sec.
Patient # 5: R.C., a 68-year-old Hispanic man, comes to your clinic with severe abdominal discomfort. He
reports a history of increased difficulty initiating urination, midstream stoppage and terminal dribbling.
R.C. complains of nocturia of 3-4 times/night. DRE reveals an enlarged prostate of approximately 25-30
gms and firm. Laboratory findings are as follow: PSA-2.8, AUA ss - 15, serum creatinine -0.8, residual
volume -150ml, flow rate -13ml/sec.
Patient # 6: G.M., a 60-year-old male, presents to your clinic with lower abdominal discomfort. He gives
a history of increased difficulty initiating urination, a significant decrease in the force of his urinary stream,
occasional midstream stoppage, and post void dribbling. Upon digital rectal examination, the prostate is
20-25 gms and benign. Laboratory findings are as follows: PSA -1.2, AUA ss-6, serum creatinine -0.5,
flow rate -20 ml/sec, residual volume -80ml.
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reflect and fully cover the curriculum which the test was designed to measure.” (Mussio,
1987). The process used for instrument development, the pretest and expert panel input
helped cover all the domains and response options which the instrument purported to
measure. Feedback from the pilot survey and the experts indicated that the instrument
was adequate by itself and did not need any additions or deletions. The final instrument
is presented in Appendix D.

Expert Opinion
One of the objectives of the study was to compare the preference of the urologists
for selection of treatment option with the guidelines. However, the guidelines do not give
specific treatment strategies for patients with moderate and severe symptoms. Hence to
obtain a recommended treatment option for the moderate (case5) and severe (case 4)
cases, expert opinions were sought. There were three experts in the panel. For the
moderate case, two of them suggested the use of alpha-blockers, whereas one suggested
the use of finasteride. Thus, it was decided that the appropriate treatment strategy for this
case would be drug therapy either in the form of alpha-blockers or finasteride. For the
severe case, all three experts suggested TURP as the treatment option, hence it was
decided that TURP would be the appropriate treatment option for this case. This
information is tabulated in table 3.2.

Survey Implementation
The survey was mailed to 294 VA urologists, 233 of whose names and practice
centers were available and 61 chief urologists whose names were not available but center
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Table 3.2: Expert opinion for use of appropriate treatment strategies for case 4 & 5.
Patient case

Expert 1

Expert 2

Expert3

Appropriate
treatment

Case 4

TURP

TURP

TURP

TURP

alphablocker

finasteride

alphablocker

drug therapy

(severe)

Case 5
(moderate)
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(alpha– blocker
&/or finasteride)

address was available. The mailing consisted of the questionnaire and a cover letter that
explained the purpose of the study. Respondents were asked to return the completed
questionnaire in the self-addressed business reply envelope provided in the package. In
order to motivate respondents to complete and return the survey, the package also
contained a raffle ticket. This required the respondents to write their name, address and
phone numbers. This would include them in a raffle drawing which had a first prize of
$100, second prize of $75 and two third prizes of $50. All the surveys sent in this mailing
were coded for follow–up purposes. All completed and returned questionnaires were
checked off from the mailing list.
The second mailing was sent about five weeks later. It consisted of the
questionnaire, the cover letter, the self-addressed business reply envelope and the raffle
ticket. The second mailing was sent to only those urologists who did not respond to the
first mailing. This was possible due to the coding procedure utilized during the first
mailing. The second cover letter was designed to stress the importance for the
respondents to participate in the study and reminded them of the raffle drawing.
Appendix E and F include copies of cover letters used in both mailings. Approximately
two weeks after the second mailing, 50 randomly selected non-respondents were called.
This was done to enhance the response rate. After a week of reminder calls, 103
urologists who had not responded and also who had not been contacted by phone calls
were identified. A non- response survey was developed and mailed to these urologists.
This non-response survey included a section which asked respondents to indicate the
reasons for not responding, a section on demographic information and a patient case to
asses the preferences of these urologists in the use of diagnostic tests for a severely
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symptomatic BPH patient. This non-response survey along with a personalized cover
letter and a self-addressed business reply envelope was mailed to the 103 identified nonrespondents. This was done to determine if differences existed between the respondents
and non-respondents. The non-response survey and the cover letter used along with it is
available in Appendix G and H, respectively.
Out of the 294 mailings, 2 questionnaires were returned as undeliverable because
of wrong or incomplete addresses. Thus, 292 surveys were assumed to reach
respondents. Of these, 114 (39.04 %) were completed and returned. For the nonresponse survey of the 103 mailings, 8 had to be disregarded either due to wrong
addresses or because response to original survey was subsequently received. Thus, 95
were assumed to reach the targeted individuals. Of these, 24 completed responses were
received, thus giving a response rate of 25.27 percent for the non-response survey.

Data Handling
Each questionnaire that was returned was checked for completeness. The two
mailings finally resulted in 114 usable responses. The Statistical Package for Social
Sciences® (SPSS) version 9 was used for data entry and statistical analysis. The data file
contained 114 cases that represented the usable responses. The data file was
meticulously checked to assure that data was free of errors.

Data Analysis
The data was checked to ensure appropriate data entry. Response analysis was
conducted to estimate the response rate for both the survey instrument and the non-
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response survey. This was followed by descriptive statistics to describe the respondents
and the non-respondents. A non-response bias analysis was conducted to determine if
differences existed between respondents and non-respondents for demographic and
practice characteristics, and preferences for selection of diagnostic tests. The following
sections deal with the analytical methods used to accomplish each of the study objectives.

Analytical Methods for Objective One: The objective was to compare the preferences of
the VA urologists with established guidelines for diagnostic management of BPH for
different levels of bothersome symptoms. To meet this objective three scores were
calculated for each of the three cases in section one of the survey instrument. The first
was the total score- which was a summation of all the diagnostic tests used for each case
in the instrument. The second was the recommended score, this was a summation of the
five tests recommended by the guidelines, which include medical history, DRE, serum
creatinine, urinalysis and AUA symptom index. The third was the optional score, this
was a summation of tests which were not recommended by the guidelines, but were
optional. This includes PSA, cystoscopy, pressure flow, uroflowmetry, intravenous
pyelogram, post voidal residual volume and others. Multiple t-tests were conducted to
determine if the three scores differed from each other for the three cases. In addition to
this, descriptive statistics were obtained for the tests and test scores for each case.

Analytical Methods for Objective Two: The objective was to compare the preferences of
the VA urologists for treating BPH with expert opinion/ established guidelines.
Descriptive statistics were obtained for all treatment options for each case. Additionally,
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percent adherence and non-adherence were calculated for each case to compare it with
the appropriate treatment option provided in the guidelines for the mild case and obtained
from experts for the moderate and severe cases.

Analytical Methods for Objective Three: This objective was to determine the effect of
demographic and practice characteristics on preferences of VA urologists for diagnosing
and treating BPH. This objective was divided in two sections, one was to assess effect of
demographics on selection of diagnostic tests and the other to assess the effect of
demographics on selection of treatment strategy. The first part was accomplished by
assessing correlations between performance of tests and number of tests performed with
demographics. The second part was accomplished by estimating chi-square statistics for
selected treatment options for each case with demographics.

Analytical Methods for Objectives Four and Five: These objectives aimed to assess the
level of agreement among VA urologists on their use of diagnostic tests/ procedures and
treatment modalities for patients presenting with BPH symptoms. To meet this objective
kappa statistic was calculated for each case in section one and two of the survey
instrument. The Z-value for this kappa statistic was estimated and its significance was
assessed using standardized tables. The kappa statistics obtained were then compared
with standard kappa values for level of agreement.

Analytical Methods for Objective Six: The objective was to determine the treatment
failure rate for BPH in the VA population and the types of switches commonly made. To

52

meet this objective, descriptive statistics were performed on the third section of the
instrument. Also rate of switch, average switch and ranks for the types of switches were
determined.

Analytical Methods for Objective Seven: The objective was to estimate the cost of
diagnosing BPH in the VA population. Standard charges for the diagnostic tests, using
CPT4 codes, were obtained from a VA center. Descriptive statistics were obtained to
determine average cost of diagnosis and range of costs for each case in section one. Also,
these costs were projected to get cost of diagnosis for BPH for all the VA centers.

Study Limitations
Limitations that could affect the generalizabiliy of the study findings may be
attributed to the following factors: (i) Confounding, (ii) Sampling (iii) Non response bias,
and (iv) The use of mail survey for data collection. Following is a discussion of the
possible influence of each of these factors on limiting the generalizability of the study.

Confounding Factors
The findings of the study might have been confounded by two factors. First, it is
possible that each center has established their own practice patterns for the management
of BPH. This may affect the preferences of the respondents. Second, it is possible that
preferences may differ from actual practice due to reasons not controlled by the
respondents. These may include availability of resources, time constraints, patient
variations etc.
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Sampling Procedure
Due to unavailability of an appropriate sample frame (list of urologists working in
all the Veteran Administration Medical Center's in the United States), a convenient
sample which was obtained after telephone calls to various centers was used. Those
centers which could not be reached were omitted from the study. Thus, it is possible that
the sample used may impose limitations to generalizability of the study results to those
who could not be reached and those, whose names were not listed in the mailing list used
for the study.

Non-response Bias
The survey was sent to 294 urologists in the VA, 2 were wrong addresses. Thus
the survey was assumed to reach 292 urologists. However, the final completed
questionnaire was returned by 114 urologists. Thus, bias could have been introduced in
the study, as respondents may be significantly different from the non-respondents with
respect to preferences in the use of diagnostic and treatment modalities for BPH
management. Also, they may be different with respect to demographic and practice
characteristics. Previous studies have demonstrated that age affects practice patterns of
urologists (Barry et al, 1997). Younger urologists prefer drug therapy and order fewer
non-recommended tests compared to older urologists. Hence, to minimize non-response
bias, non-response analysis was conducted to test for any possible differences.
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Use of Mail Questionnaire
A mail questionnaire was used to collect data for respondents. This kind of
survey instrument has many disadvantages that may introduce biases in the results of the
study. These include low response rate and lack of control over item non-response. Also
mail surveys are insensitive to substitution of respondents and may fail to provide
standardized understanding of survey questions among respondents. However, financial
and time constraints directed the use of mail survey. The questionnaire was pre-tested for
validity, readability and time consideration. This indicated that the survey had good
clarity and readability and required about 5 minutes for completion.
This chapter provided a detailed description of the methodology employed for the
selection of the sample for the study, the development of the survey instrument and the
implementation of the study. In the next chapter, the results of the analysis conducted for
accomplishing the goal and objectives of the study will be presented.
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CHAPTER FOUR
RESULTS AND DISCUSSION

This chapter will present the analytical tools employed to accomplish the study
goal and objectives, and the results obtained from such analysis, and provide a discussion
of the study results. The Statistical Package for the Social Sciences (SPSS®) was
employed for data entry, data coding and data analysis. Prior to presenting the results for
the study objectives, survey response analysis including response rate estimation and
non-response bias assessment will be presented.

Survey Response Analysis
Survey response analysis involves determination of response rate and estimation
of any non-response bias. The following section describes the procedure used to
determine the survey response rate and methods employed to estimate the non-response
bias for this study.

Response Rate
Response rate analysis involves an estimation of the number of subjects of the
total sample who responded and were used in the analysis and interpretation of the study
results. Response rate was determined using the procedure in Table 4.1. The survey was
mailed to 294 urologists practicing in Veterans Administration Medical Centers (VAMC)
all over the United States. Of these, 2 questionnaires were returned because of
incomplete or wrong addresses. Thus, 292 surveys were assumed to have reached the
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Table 4.1: Response rate calculations

Total sample population selected = 294
Wrong addresses = 2
Effective population reached = 292
Responses received = 114
Response rate = (114/292)*100 = 39.04 %
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respondents. A total of 114 completed responses were received yielding a response rate
of approximately 39 percent. Although a higher response rate is always desirable, the
response in this study was considered adequate for analytical purposes and was
comparable to other studies surveying urologists (Barry et al, 1997; Oh, Colberg,
Ornstein, Johnson, Chan & Virgo, 1999).
Additionally, the data was reviewed to assess response rate from the states and the
22 Veterans Integrated Systems Network (VISN’s). The results of this analysis are
presented in Tables 4.2 and 4.3. Responses were obtained from 21 of the 22 VISN’s.
The only VISN that was not represented was VISN 5 (VA Capitol Network). The 114
responses that were obtained covered 42 States in the U.S. No responses were obtained
from the states of Colorado, Hawaii, Idaho, Maryland, Nevada, Wyoming, Washington
DC, and Puerto Rico. The state of Maine and the territories of Guam, and Virgin Islands
were not represented in the study sample. Also, responses were obtained from 80 of the
149 centers that were part of the study sample.

Non-Response Bias Assessment
The non-response survey (Appendix G) was mailed to 103 urologists who did not
respond to the first two mailings. However, since 4 of these replied after the mailing of
the non-response survey and 4 were returned due to wrong addresses, the final number of
non-response surveys were assumed to be 95. A total of 24 completed surveys were
returned, thus giving a response rate of approximately 25 percent. Table 4.4 depicts the
reasons the respondents gave for not responding to the main survey. The most common
reasons were lack of time (26.15) followed by “don’t like to respond to surveys” (17.4%)

58

Table 4.2: Response rate analysis based on VISN’s represented
VISN number

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Total

Responses

Surveys

received

sent

Response rate (%)

7
2
10
5
0
4
7
8
11
4
4
3
4
2
8
11
6
5
3
3
2
5

18
8
22
11
8
12
13
16
18
16
9
10
4
12
18
27
10
12
5
8
6
29

38.89
25.00
45.45
45.45
0.00
33.33
53.85
50.00
61.11
25.00
44.44
30.00
100.00
16.67
44.44
40.74
60.00
41.67
60.00
37.50
33.33
17.24

114

292

39.04
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Table 4.3: Response rate analysis based on state represented
State
Alabama
Arkansas
Arizona
California
Connecticut
Delaware
Florida
Georgia
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin

Responses received

Surveys sent

1
4
3
8
1
2
8
3
4
1
1
2
4
2
2
1
2
1
6
1
1
1
2
2
10
2
1
4
2
2
2
2
3
1
6
8
2
1
2
1
2
1

1
10
7
32
2
4
15
5
6
1
6
4
8
3
12
8
2
8
13
1
6
1
3
5
27
7
1
17
4
2
9
3
6
1
10
9
2
1
4
3
4
4

60

Response rate (%)
100.00
40.00
42.86
25.00
50.00
50.00
53.33
60.00
66.67
100.00
16.67
50.00
50.00
66.67
16.67
12.50
100.00
12.50
46.15
100.00
16.67
100.00
66.67
40.00
37.04
28.57
100.00
23.53
50.00
100.00
22.22
66.67
50.00
100.00
60.00
88.89
100.00
100.00
50.00
33.33
50.00
25.00

Table 4.4: Reasons for not responding to the main survey (N=24)

Reason

N

Not enough time to complete survey

6

26.1

Don’t like to respond to surveys

4

17.4

Not enough incentive to complete survey

3

13.0

Survey was misplaced

2

8.7

Not interested in such studies

2

8.7

Did not receive the survey

2

8.7

Survey was too long

2

8.7

Forgot about survey

1

4.3

Topic was irrelevant

0

0.0

Not enough information about study

0

0.0

Other (not a urologist, vacation, conference)

4

17.4
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Percent (%)

and the lack of enough incentive to complete the survey (13%). Among the other
reasons, 8.7% reported misplacing the survey, not being interested, not receiving the
survey and length of the survey as a problem. Also, a small number of individuals
(4.3%) reported forgetting about the survey.
Table 4.5 presents demographic and practice characteristics of the respondents to
the non-response survey. Of the 18 respondents who responded to the question, 16
(88.89%) were males and 2 (11.12%) were females. Also, 45 percent were less than 40
years of age, 35 percent were between 40-49, 20 percent were 60 or older. All the
urologists reported practicing in a center that used a formulary. The average number of
urologists at each center was almost 4. The number of new BPH patients visiting each
center every month ranged from 2 to 100 with a mean of 40.67 patients. Each urologist
was in practice for an average of 88 months (7.33 years).
The respondents and non-respondents were compared for the demographic
variables and practice characteristics to determine if they significantly differed from each
other. The variables included for analysis were age, gender, number of urologists at the
center of practice, years of practice at current center and number of new BPH patients
visiting the center per month. Presence of formulary status could not be used for nonresponse analysis as all urologists reported presence of a formulary at their center. Chisquares were used for comparison of age and gender whereas ANOVA's were used for
comparison of the other variables. The result of this analysis is reported in Table 4.6.
Results indicate no significant differences between the two groups of respondents and
non-respondents on any of these variables.
The two groups were also compared for their preferences of utilization of
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Table 4.5: Demographic and practice characteristics of respondents
of non-response survey.
Characteristics

N

Percent (%)

16
2
18

88.89
11.11
100.00

9
7
0
4
20

45.00
35.00
0.00
20.00
100.00

21
0
21

100.00
0.00
100.00

Gender
Male
Female
Total
Age
Less than 40 years
40-49 years
50-59 years
60 years or older
Total
Presence of formulary
Yes
No
Total

Range

Mean+Std.Dev

Number of urologists
practicing at VAMC

1-7

3.63+1.63

Months in practice
at present VAMC

24 - 308

88.00+66.85

Number of new BPH
patients visiting the
VAMC per month

2 - 100

40.67+28.02
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Table 4.6: Analysis of non-response bias for demographic and practice
characteristics
Characteristics

Respondents Non-respondents

Test Statistics

Significance

X2 = 1.235

0.266

X2 = 7.043

0.071

F = 1.260

0.263

F = 0.014

0.905

F = 0.176

0.676

Demographics
Gender
Male
Female
Age
> 40 years
40 – 49 years
50 – 59 years
60 years or older

95.4%
4.6%

29.1%
23.6%
23.6%
23.6%

88.9%
11.1%

45%
35%
0%
20%

Practice Characteristics
Number of
3.18+1.66
urologists at VAMC
Years of practice
at present center

3.63+1.63

90.49+88.69 88.00+66.85

Number of new
36.09+39.48 40.67+287.07
BPH patients per month
Statistically significant (p < .05)
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diagnostic tests for one of the patient case on the main survey which was also included as
a part of the non-response survey. The results of this analysis are summarized in Table
4.7. Chi-squares were used compare the preferences of diagnostic tests between the two
groups. Results indicate that the two groups did not differ significantly in their
preferences for medical history, serum creatinine, AUA, pressure flow, uroflowmetry,
post voidal residual volume and other tests. However, the two groups differed
significantly in their preference for digital rectal examination (X2 = 6.936, p = 0.058),
urinalysis (X2 = 4.954, p = 0.026), PSA (X2 = 9.427, p = 0.006), cystoscopy (X2 = 6.407,
p = 0.011), and intravenous pyelogram (X2 = 4.221, p = 0.040). Also, the respondents
included a cohort of urologists who preferred these tests more than the non-respondents.
Of these, DRE and urinalysis were tests recommended by the guidelines while the other
three, PSA, cystoscopy, and intravenous pyelogram were optional tests.
Thus, the results of the study demonstrate non-response bias, such that the nonrespondents prefer fewer number of optional tests compared to respondents for diagnosis
of a severely symptomatic BPH patient compared to the respondents. Also, the nonrespondents included a group of urologists who may prefer some of the recommended
tests, especially DRE and urinalysis, to a lesser extent than the respondents. Thus, this
imposes limitations on the generalizability of results to the entire group of VA urologists.
Hence, readers are cautioned in their interpretation of the study results.
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Table 4.7: Analysis of non-response bias for preference of diagnostic tests for
Case 3 (high degree of bothersome symptoms)
Characteristics

Medical history
Yes
No
Digital rectal examination
Yes
No
Urinalysis
Yes
No
Serum creatinine
Yes
No
PSA
Yes
No
AUA symptom score
Yes
No
Cystoscopy
Yes
No
Pressure flow
Yes
No
Uroflowmetry
Yes
No
Intravenous Pyelogram
Yes
No
Post voidal residual volume
Yes
No
Others
Yes
No

Respondents Nonrespondents

96.5%
3.5%
98.2%
1.8%
97.4%
2.6%
79.8%
20.2%
92.1%
7.9%
74.6%
25.4%
86.8%
13.2%
6.1%
84.3%
43.0%
57.0%
77.2%
22.8%
66.7%
33.3%
22.8%
77.2%

Test Statistics

Significance

X2 = 3.589

0.058

X2 = 6.936

0.008*

X2 = 4.954

0.026*

X2 = 2.332

0.127

X2 = 9.427

0.006*

X2 = 0.004

0.948

X2 = 6.407

0.011*

X2 = 1.348

0.246

X2 = 3.617

0.057

X2 = 4.221

0.040*

X2 = 0.865

0.352

X2 = 0.328

0.567

87.0%
13.0%
87.0%
13.0%
87.0%
13.0%
65.2%
34.8%
69.9%
30.4%
73.9%
26.1%
65.2%
34.8%
13.0%
87.0%
21.7%
78.3%
56.5%
43.5%
56.5%
43.5%
17.4%
82.6%

*

Statistically significant (p < .05)
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Demographic and Practice Characteristics
Demographic and practice characteristics of the respondents are presented in
Table 4.8. Of the respondents, 103 were male (95.37%) and 5 (4.63%) were female.
Also, 32 (29.09%) were less than 40 years of age, 26 (23.64%) were between 40 to 49, 26
(23.64%) were between 50 to 59 and 26 (23.64%) were 60 or older. All urologists
reported practicing in a VAMC that used a formulary. Of these, 103 (90.4%) reported
having terazosin on their formulary, 15 (13.2%) having doxazosin, 34 (29.8%) having
prazosin and 73 (64.9%) having finasteride.
Respondents were asked to indicate the number of urologists practicing at their
center. The number of urologists at each VAMC ranged from 0 to 8 with an average of
3.19 urologists at each center. The respondents indicated that an average of 36 new BPH
patients visited their center per month. For the purpose of data analysis, the number of
years of practice was converted into months. Thus, months of practice ranged from 1 to
360 with an average of 90.50 months (7.54 years).

Objective One Results
The first objective of this study was to compare preferences of VA urologists for
diagnosing BPH with AHRQ (formerly AHCPR) guidelines. Table 4.9 indicates
frequencies and percentages for diagnostic tests preferred by respondents for each BPH
case of Section I of the survey. Almost 97 percent of the respondents preferred use of
medical history, while 98 percent preferred use of digital rectal examination for all the
three cases. Preference for urinalysis increased from 93 to almost 97 percent as degree of
bothersome symptoms increased from low to medium to high. Preferences for serum
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Table 4.8: Demographic and practice characteristics of respondents
Characteristics

N

Percent (%)

Total

103
5
108

95.37
4.63
100.00

Less than 40
40-49
50-59
60 or older
Total

32
26
26
26
110

29.09
23.64
23.64
23.64
100.00

Presence of formulary
Yes
No
Total

113
0
113

100.00
0.00
100.00

Drugs on formulary
Terazosin
oxazosin
Prazosin
Finasteride

103
15
34
73

90.40
13.20
29.80
64.90

Gender
Male
Female

Age

Range

Mean+Std.Dev

Number of urologists
practicing at VAMC

0-8

3.19+1.66

Months in practice
at present VAMC

1 - 360

90.50+88.69

Number of new BPH
patients visiting the
VAMC per month

0 - 200

36.09+39.48
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Table 4.9: Preferences of urologists for diagnostic tests in BPH patients
Diagnostics tests

Degree of bothersome symptoms
Low
Medium
(Patient # 2*)
(Patient # 1*)
N
%
N
%

High
(Patient # 3*)
N
%

110
112
106
63
87

96.5
98.2
93.0
55.3
76.3

110
112
110
65
88

96.5
98.2
96.5
57.0
77.2

110
112
111
91
85

96.5
98.2
97.4
79.8
74.6

AHRQ optional tests
PSA
109
Cystoscopy
24
Pressure flow
8
Uroflowmetry
54
Intravenous pyelogram
7
Post voidal residual volume 80
Others **
15

95.6
21.1
7.0
47.4
6.1
70.2
13.2

106
19
7
58
8
83
18

93.0
16.7
6.1
50.9
7.0
72.8
15.8

105
99
7
49
87
76
26

92.1
86.8
6.1
43.0
77.2
66.7
22.8

AHRQ recommended tests
Medical history
Digital rectal exam
Urinalysis
Serum creatinine
AUA symptom score

*

Patient # 1: B.T., a 66-year-old white male comes to your clinic with bothersome urinary symptoms. He
complains of increased frequency, incomplete bladder emptying and occasional burning sensation. He
denies any hematuria. He also reports occasional post void dribbling and nocturia of about 3-4 times a
night.
Patient # 2: J.J., a 54-year-old African-American man, presents to your office with lower abdominal
discomfort. He reports occasional difficulty initiating urination, midstream stoppage and post void
dribbling. He also complains of nocturia of about 2 times a night.
Patient # 3: M.J., a 72-year-old white man presents to you with history of blood in the urine. He gives also
a history of increasing difficulty initiating urination, frequent midstream stoppage, frequent burning on
urination, and post void dribbling. He also reports a decrease in the force and caliber of his urinary stream
as well as incomplete bladder emptying and complains of nocturia of more than 4 times/night and daytime
frequency of more than 10 times/day.
**Other tests for patient #1 included; cytology, pelvic ultra scan, bladder ultrasound, CDB, and CBC, for
patient #2 included; pelvic ultra scan, CBD, and bladder scan, and for patient #3 included CTS, pelvic ultra
scan, CBD, CBC, urine cytology, urine culture, renal sonography, and bladder scan
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creatinine increased from 55 to 57 percent as degree of bothersome symptoms increased
from low to medium and increased to almost 80 percent as degree of bothersome
symptoms increased to high. More than three fourths of the respondent urologists
preferred to use the AUA symptom index irrespective of the degree of bothersome
symptoms. These were all the tests recommended by the guidelines. Of the optional
tests, PSA was highly preferred for all three cases (92 to 96 %), whereas pressure flow
was least preferred (6 to 7%). Uroflowmetry and measurement of post voidal residual
volume had moderate preference with the range of preference being 43 to 50 percent and
66 to 70 percent, respectively. Both the invasive procedures of cystoscopy and
intravenous pyelogram were less preferred for the cases with low and medium degrees of
bothersome symptoms but their preference increased substantially for the case with high
level of bothersome symptoms. Almost 87 percent of the urologists recommended the
use of cystoscopy while 78 percent recommended the use of intravenous pyelogram for
the patient with high degree of bothersome symptoms.
To compare the preferences of the VA urologists with guidelines, three scores
were calculated for each case.

The first score was a total score obtained as a result of

summation of all the diagnostic tests preferred by the respondents for each of the three
cases. The second score was the recommended score, obtained as a sum of the tests
recommended by guidelines which included medical history, DRE, serum creatinine,
urinalysis and AUA symptom index. The remaining tests were summed to obtain the
third score called the optional score. The mean and range for these scores for each of the
case is presented in Table 4.10. The average number of tests for the cases with low and
medium bothersome symptoms was approximately 7 while it was 8 for the case with high
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Table 4.10: Comparison of preferences of VA urologists for diagnostic tests for BPH
with guidelines
Cases

Range

Mean+Std.Dev

Low (patient case 2)

0 - 10

6.798 + 1.705

Medium (patient case 1)

0 - 10

6.877 + 1.745

High (patient case 3)

0 - 12

8.412 + 1.818

Low (patient case 2)

0-5

4.193 + 1.012

Medium (patient case 1)

0-5

4.254 + 0.976

High (patient case 3)

0-5

4.464 + 0.904

Low (patient case 2)

0-5

2.605 + 1.027

Medium (patient case 1)

0-5

2.623 + 1.108

High (patient case 3)

0-7

3.947 + 1.174

Total test scores

Recommended test scores

Optional test scores
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degree of bothersome symptoms. The recommended test scores ranged between 4 and 5
and increased in number with increasing degree of bothersome symptoms. The optional
test scores were almost the same for the cases with low and medium bothersome
symptoms (mean =2.6) but increased for the case with high bothersome symptoms
(mean=3.9).
T-tests were conducted to determine whether urologists' preference for diagnostic
tests differed for the three cases based on the number of tests preferred. The results of this
analysis are summarized in Table 4.11. The case with high degree of bothersome
symptoms (case 3) significantly differed for all the three computed scores - total,
recommended and optional- from the cases with low (case 2) (t = -14.00, t =-5.25, t =13.48) and medium (case1) (t =-13.50, t =-4.44, t =-13.13) degree of bothersome
symptoms, respectively.

Discussion for Objective One Results
The guidelines recommend use of four tests for initial evaluation of a patient
presenting with BPH symptoms. These include medical history, digital rectal
examination, urinalysis and serum creatinine. It also recommends the use of the AUA
symptom score for quantification of symptoms. Almost all the respondents preferred the
use of the first three tests for diagnosis of the patient cases. However, serum creatinine
was less preferred compared to the first three. This test was preferred more by
respondents for case 3, which presented high bothersome symptoms compared to the first
two cases. No definite explanation can be provided for such preferences. AUA symptom
index was also preferred less compared to the first three tests with a range of 85 to 88
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Table 4.11: Comparison of preferences of VA urologists for diagnostic tests for BPH
with guidelines based on severity levels.
Pairs

Mean+S.D.

Test Statistics

Significance

Total test scores
Low (patient #2)
Medium (patient #1)

6.798+1.705
6.877+1.745

t = +0.824

0.412

Low (patient #2)
High (patient #3)

6.798+1.705
8.412+1.818

t = -14.008

0.000*

Medium (patient #1)
High (patient #3)

6.877+1.745
8.412+1.818

t = -13.508

0.000*

Low (patient #2)
Medium (patient #1)

4.193+1.012
4.254+0.976

t = +1.617

0.109

Low (patient #2)
High (patient #3)

4.193+1.012
4.464+0.904

t = -5.249

0.000*

Medium (patient #1)
High (patient #3)

4.254+0.976
4.464+0.904

t = -4.441

0.000*

Low (patient #2)
Medium (patient #1)

2.605+1.027
2.623+1.108

t = +0.220

0.826

Low (patient #2)
High (patient #3)

2.605+1.027
3.947+1.174

t = -13.482

0.000*

Medium (patient #1)
High (patient #3)

2.623+1.108
3.947+1.174

t = -13.135

0.000*

Recommended test scores

Optional test scores

Statistically significant (p < .05)
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percent for the three cases. This is an important index, which is utilized for classification
of the severity of the patient symptoms. Depending on this classification appropriate
treatment option(s) can be selected. This tool has been tested, validated and found to be
the most reliable instrument to quantify BPH related symptoms (Barry, Fowler, O’Leary,
Bruskewitz, Holtgrewe et al, 1992). Also, there have been studies which show that it
captures clinically important changes in patients’ condition (Barry, Fowler, O’Leary,
Bruskewitz, Holtgrewe et al, 1992). Thus, lower preference for this index could result in
utilization of inappropriate treatment strategy, and thereby result in inefficient use of
resources. Measurement of PSA level is an optional test in the guidelines. However,
higher preference was shown for this test among respondents, with a range of 92 to 95
percent for the three cases. Though this is an optional test, it is used extensively for
screening of prostate cancer. Thus, it is likely that higher preference for this test was
shown by respondents since they may want to rule out the possibility of prostate cancer.
Among the other optional tests like pressure flow, uroflowmetry and post-voidal residual
volume (PVRV), pressure flow was least preferred followed by uroflowmetry and finally
PVRV. The two invasive optional procedures, cystoscopy and intravenous pyelogram,
were less preferred for case one and two (medium and low degree of bothersome
symptoms). However, for case three (high degree of bothersome symptoms) both tests
were more preferred. This may be due to the fact that the guidelines recommend the use
of cystoscopy only if invasive treatment procedures are to be utilized (AHCPR, 1994).
The patient cases were formulated such that case two presented a patient with low
bothersome symptoms, case one with medium symptoms and case three with high
symptoms. The average number of both recommended and optional tests increased as the
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degree of bothersome symptoms of the patient increased. The number of tests preferred
was not significantly different between case one and two, but were significantly different
from case three where the degree of bothersome symptoms were high. Thus, the
preferences of VA urologists demonstrate adherence to the guidelines for the
recommended tests. However, the number of tests preferred increased with increasing
severity of symptoms. Also, the number of tests performed on a patient with high degree
of bothersome symptoms is significantly higher compared to patients with low to medium
degree of symptoms. The results of this study are comparable to the results of the
national urologists’ study (Barry et al, 1997) and the study conducted by Gee, Holtgrewe
et al (1995). Both studies reported practices consistent with BPH guidelines in terms of
examination and tests for men with suspected BPH. Thus, this study further establishes
conformation to guidelines by urologists for diagnostic management of BPH, especially
in the VA population.

Objective Two Results
The second objective of the study was to compare preferences of VA urologists
for treating BPH with guidelines/expert opinion. Table 4.12 summarizes the treatment
preferences of the urologists for the three cases. For the mild case, 77 (67.5%) preferred
alpha-blockers, 36 (31.6%) preferred watchful waiting, 2 (1.8%) preferred finasteride, 2
(1.8%) preferred TUIP and 19 (16.7%) preferred other options not listed. For the
moderate case (patient 5), 101 (88.6%) preferred alpha-blockers, 13 (11.4%) preferred
TURP, 4 (3.5%) preferred finasteride, , 4 (3.5) preferred TUIP, 2 (1.8%) preferred
TUVP, 1 (0.9%) preferred laser prostactomy, 1 (0.9%) preferred watchful waiting, and 27
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Table 4.12: Preferences of urologists for treatment options used in BPH patients
Treatment option

Watchful waiting
Alpha-blockers
Finasteride
Balloon Dilation
TURP
TUIP
Open Prostactomy
Laser Prostactomy
TUVP
Other

Severity of BPH
Mild
Moderate
(Patient # 5) *
(Patient # 6)*
N
%
N
%

Severe
(Patient # 4) *
N
%

36
77
2
0
0
2
0
0
0
19

0
72
33
0
54
0
2
3
4
30

31.6
67.5
1.8
0.0
0.0
1.8
0.0
0.0
0.0
16.7

1
101
4
0
13
4
0
1
2
27

0.9
88.6
3.5
0.0
11.4
3.5
0.0
0.9
1.8
23.7

0.0
63.2
28.9
0.0
47.4
0.0
1.8
2.6
3.5
26.3

*

Patient # 4: A.D., a 75-year-old African-American male comes with the problem of urinary incontinence.
He also gives a history of difficulty initiating urination, midstream stoppage and terminal dribbling. Rectal
examination reveals an enlarged prostate of 50-55 gms. A.D. gives a history of nocturia approximately 4-5
times a night, daytime urinary frequency of 8-10 times a day and he reports of blood in urine. Laboratory
findings are as follows: PSA -4.1, AUA ss -28, serum creatinine -1.2, residual volume -300ml, flow rate 7ml/sec.
Patient # 5: R.C., a 68-year-old Hispanic man, comes to your clinic with severe abdominal discomfort. He
reports a history of increased difficulty initiating urination, midstream stoppage and terminal dribbling.
R.C. complains of nocturia of 3-4 times/night. DRE reveals an enlarged prostate of approximately 25-30
gms and firm. Laboratory findings are as follow: PSA-2.8, AUA ss - 15, serum creatinine -0.8, residual
volume -150ml, flow rate -13ml/sec.
Patient # 6: G.M., a 60-year-old male, presents to your clinic with lower abdominal discomfort. He gives
a history of increased difficulty initiating urination, a significant decrease in the force of his urinary stream,
occasional midstream stoppage, and post void dribbling. Upon digital rectal examination, the prostate is
20-25 gms and benign. Laboratory findings are as follows: PSA -1.2, AUA ss-6, serum creatinine -0.5,
flow rate -20 ml/sec, residual volume -80ml.
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(23.7%) preferred use of other options not listed in the questionnaire. Similarly, for the
severe case (patient 4) 72 (63.2%) respondents preferred alpha-blockers, 54 (47.4%)
preferred TURP (surgery), 33 (28.9%) preferred finasteride, 4 (3.5%) preferred TUVP, 3
(2.6%) preferred laser prostactomy, 2 (1.8%) preferred open prostactomy, and 30 (26.3%)
preferred the use of other options. The other options for all three cases primarily
consisted of additional diagnostic tests like cystoscopy, intravenous pyelogram,
ultrasound etc.
The above responses were compared with the guidelines and to expert opinion to
determine adherence. The recommended option for the mild case was watchful waiting
(from guidelines) whereas for the moderate case it was drug therapy (from expert
opinion) and for the severe case it was TURP (expert opinion). For the moderate and
severe cases the guidelines did not recommend specific treatment options. Hence, expert
opinion was used to compare respondent’s preferences. Of the 114 respondents, 36
(31.6%) favored watchful waiting for the mild case, while 78 (68.4%) respondents
preferred other options. For the moderate case, 101 (88.6%) respondents preferred the
use of alpha-blocker to control symptoms and 5 preferred the use of finasteride.
However, since the questionnaire allowed selection of multiple options, close study of the
data indicated that the 5 respondents who preferred use of finasteride also preferred use
of alpha-blockers. Hence, 101 respondents preferred use of drug therapy for controlling
symptoms. Thus, the percent adherence for the moderate case was 88.60. Similarly for
the severe case, of the 114, 54 preferred TURP. Thus, the percent adherence was 47.4
(see Table 4.13).
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Table 4.13: Comparison of preferences of VA urologists for treatment of BPH with
guidelines/expert opinion
.
Cases

Recommended
treatment option

Percent
Adherence

Mild (patient # 6)

Watchful waiting

31.60

68.42

Moderate (patient #5)

Drug therapy*

88.60

11.40

Severe (patient #4)

TURP*

47.40

52.60

*

Percent
Non-adherence

These cases were compared with expert opinion, as guidelines did not recommend
specific treatment options.
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Discussion for Objective Two Results
The guidelines recommend watchful waiting as the strategy of choice for patients
with mild symptoms. However, only about 32 percent of the urologists preferred this
option for case 6, a patient with mild symptoms. Majority of the respondents (68
percent) preferred use of alpha-blockers for this case. This may result in inappropriate
utilization of resources. For moderate and severe cases the guidelines do not recommend
any particular treatment option. Hence for these two patient cases urologists’ preferences
were compared with expert opinion. The experts preferred drug therapy (alpha-blockers
and/or finasteride) for the patient with moderate symptoms (case 5) and TURP for the
patient with severe symptoms (case 4). Among the respondent urologists approximately
89 percent of respondents preferred drug therapy for the moderate case, whereas
approximately 48 percent of the respondents preferred TURP for the severe case. Also, a
large percentage of the respondents preferred the use of drug therapy either in the form of
alpha-blockers or finasteride for the severe case, with alpha-blockers being preferred to a
greater extent. None of the respondents showed preference for use of balloon dilation in
any of the cases. Thus the respondents preferred the use of alpha-blockers for all the
cases, irrespective of the symptom severity. In other words, alpha-blockers are being
recommended when pharmacological therapy is not required and also when surgery is a
better alternative for managing the symptoms. This result is not congruent with that
shown by Gee et al (1997). Gee et al (1997) found watchful waiting to be the most
preferred first line of therapy for patients with mild symptoms, alpha-blockers for
moderate symptoms and TURP as the preferred first line therapy for severe symptoms.
However, the results show some consistency with the national survey of urologists which
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demonstrated use of pharmacological therapy when not required (Barry et al, 1997).
Also, it shows some consistency with findings of Bruskewtiz (1999) who demonstrated
that alpha-blockers was employed most of the time for patients with severe symptoms.
But, Bruskewitz also demonstrated that watchful waiting was used 77% of the time for
men with mild symptoms. Thus though VA urologists do not conform too well with
guidelines and expert opinion in their preferences for therapeutic management of BPH
symptoms, their preferences support previous findings reported in literature.

Objective Three Results
The third objective of the study was to determine the effect of demographic and
practice characteristics on the preferences of VA urologists for diagnosing and treating
BPH. This analysis was divided into two sections, the first assessed the effect of
demographic characteristics on the preferences of VA urologists for diagnostic tests, and
the second assessed their effects on preferences for treatment options. Correlations were
conducted for the first section. This was conducted in two ways. A sum score was
computed for each diagnostic test depending on whether it was recommended for all the
three cases in Section I of the survey. Thus, if a test was recommended for all the three
cases it would have a score of three but if it was not recommended for any, it would have
a score of zero. Correlations were obtained between the computed scores for every
diagnostic test and the demographic and practice characteristics. The demographic and
practice characteristics used included number of urologists, years of practice, number of
new BPH patients visiting per month, and age of urologist. The results of this analysis
are presented in Tables 4.14 to 4.24. Additionally, correlations were conducted between
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Table 4.14: Correlation matrix for test score of medical history
Variables

Medical
history

Number of
urologists

Medical history

1.000

Number of
Urologists

-.081

1.000

Years of
practice

-.100

-.051

1.000

Number of
BPH patients

.012

.128

.089

1.000

Age

-.189*

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.15: Correlation matrix for test score of digital rectal examination (DRE)
Variables

DRE

Number of
urologists

DRE

1.000

Number of
Urologists

-.147

1.000

Years of
practice

-.109

-.051

1.000

Number of
BPH patients

-.005

.128

.089

1.000

Age

-.133

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.16: Correlation matrix for test score of urinalysis
Variables

Urinalysis

Number of
urologists

Urinalysis

1.000

Number of
Urologists

-.229*

1.000

Years of
practice

.027

-.051

1.000

Number of
BPH patients

-.003

.128

.089

1.000

Age

.017

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.17: Correlation matrix for test score of serum creatinine
Variables

Serum
creatinine

Number of
urologists

Serum creatinine

1.000

Number of
Urologists

-.204*

1.000

Years of
practice

-.012

-.051

1.000

Number of
BPH patients

.072

.128

.089

1.000

Age

-.218*

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.18: Correlation matrix for test score of prostate specific antigen level (PSA)
Variables

PSA

Number of
urologists

PSA

1.000

Number of
Urologists

-.011

1.000

Years of
practice

-.032

-.051

1.000

Number of
BPH patients

.069

.128

.089

1.000

Age

-.112

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.19: Correlation matrix for test score of AUA symptom index
Variables

AUA

Number of
urologists

AUA

1.000

Number of
Urologists

-.108

1.000

Years of
practice

.024

-.051

1.000

Number of
BPH patients

.066

.128

.089

1.000

Age

-.104

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.20: Correlation matrix for test score of cystoscopy
Variables

Cystoscopy

Number of
urologists

Cystoscopy

1.000

Number of
Urologists

.064

1.000

Years of
practice

.039

-.051

1.000

Number of
BPH patients

-.063

.128

.089

1.000

Age

-.079

-.294*

.421*

.012

*

Statistically significant (p < .05)

87

Years of
practice

Number of
Age
BPH patients

1.000

Table 4.21: Correlation matrix for test score of pressure flow studies
Variables

Pressure
flow

Number of
urologists

Pressure flow

1.000

Number of
Urologists

.039

1.000

Years of
practice

-.090

-.051

1.000

Number of
BPH patients

-.023

.128

.089

1.000

Age

.093

-.294*

.421*

.012

*

Statistically significant (p < .05)

88

Years of
practice

Number of
Age
BPH patients

1.000

Table 4.22: Correlation matrix for test score of uroflowmetry
Variables

Uroflowmetry

Number of
urologists

Uroflowmetry

1.000

Number of
Urologists

.031

1.000

Years of
practice

-.073

-.051

1.000

Number of
BPH patients

.034

.128

.089

1.000

Age

-.148

-.294*

.421*

.012

*

Statistically significant (p < .05)

89

Years of
practice

Number of
Age
BPH patients

1.000

Table 4.23: Correlation matrix for test score of intravenous pyelogram (IVP)
Variables

IVP

Number of
urologists

IVP

1.000

Number of
Urologists

-.051

1.000

Years of
practice

-.004

-.051

1.000

Number of
BPH patients

-.108

.128

.089

1.000

Age

.155

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

Table 4.24: Correlation matrix for test score of post voidal residual volume
(PVRV)
Variables

PVRV

Number of
urologists

PVRV

1.000

Number of
Urologists

-.152

1.000

Years of
practice

-.136

-.051

1.000

Number of
BPH patients

-.075

.128

.089

1.000

Age

-.183

-.294*

.421*

.012

*

Statistically significant (p < .05)
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Years of
practice

Number of
Age
BPH patients

1.000

the recommended, optional and total score and the demographic and practice
characteristics. The details of how these scores were computed is explained in section for
objective one of Results chapter (Chapter 4, page 70). The results of these correlations
are presented in Tables 4.25 to 4.33.
The correlations which showed significant associations were: age was negatively
associated with medical history test score (r = -.189), and positively associated with
serum creatinine test score (r =.218), number of urologists was negatively associated with
urinalysis test score (r =-.229) and serum creatinine test score (r =-.204). Also, number
of urologists was negatively associated with recommended score for case1(r = -.250),
recommended score for case 2 (r =-.266), total score for case 1 (r =-.211) and total score
for case 2 (r =-.259). Additionally, age was negatively associated with optional score for
case 3 (r =-.268) and total score for case 3 (r =-.208).
To assess the effects of demographics and practice characteristics on preferences
for treatment options, chi-squares statistics were conducted. To do so, the variables of
years of practice at present center and number of new BPH patients seen per month were
re-coded to get categorical variables. Thus, years of practice was divided into 5
categories: less than 2 years, 2 to less than 4 years, 4 to less than 7 years, 7 to less than 10
years and 10 years and above. Similarly number of new BPH patients seen per month
was divided into 4 categories: less than 10, 11 to 20, 21 to 40 and greater than 40. Chisquares were conducted for each case in section two, i.e. case 4, case 5, and case 6.
Preferences for some of the treatment options were low. Hence they were not included in
the chi-squares analysis, since they would result in a greater percentage of empty cells.
Thus, chi-square tests were conducted for the treatment options of finasteride, alpha-
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Table 4.25: Correlation matrix for recommended test score for case 1
Variables

Recommended
test score 1

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Recommended**
test score 1

1.000

Number of
Urologists

-.250*

1.000

Years of
practice

.006

-.051

1.000

Number of
BPH patients

.096

.128

.089

1.000

Age

.033

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Recommended test score 1= Medical History + DRE +Serum creatinine + Urinalysis
+ AUA symptom score (use of these tests for case 1)
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Table 4.26: Correlation matrix for recommended test score for case 2
Variables

Recommended
test score 2

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Recommended **
test score 2

1.000

Number of
Urologists

-.266*

1.000

Years of
practice

-.020

-.051

1.000

Number of
BPH patients

.014

.128

.089

1.000

Age

.045

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Recommended test score 2= Medical History + DRE +Serum creatinine + Urinalysis
+ AUA symptom score (use of these tests for case 2)
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Table 4.27: Correlation matrix for recommended test score for case 3
Variables

Recommended
test score 3

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Recommended **
test score 3

1.000

Number of
Urologists

-.107

1.000

Years of
practice

-.052

-.051

1.000

Number of
BPH patients

.069

.128

.089

1.000

Age

-.054

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Recommended test score 3= Medical History + DRE +Serum creatinine + Urinalysis
+ AUA symptom score (use of these tests for case 3)
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Table 4.28: Correlation matrix for optional test score for case 1
Variables

Optional
test score 1

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Optional **
test score 1

1.000

Number of
Urologists

-.113

1.000

Years of
practice

-.094

-.051

1.000

Number of
BPH patients

-.132

.128

.089

1.000

Age

.008

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Optional test score 1=PSA + Cystoscopy + Pressure flow + Uroflowmetry +
Intravenous pyelogram + Post voidal residual volume + others (use of these tests for
case 1)
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Table 4.29: Correlation matrix for optional test score for case 2
Variables

Optional
test score 2

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Optional **
test score 2

1.000

Number of
Urologists

-.163

1.000

Years of
practice

-.089

-.051

1.000

Number of
BPH patients

-.080

.128

.089

1.000

Age

.005

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Optional test score 2=PSA + Cystoscopy + Pressure flow + Uroflowmetry +
Intravenous pyelogram + Post voidal residual volume + others (use of these tests for
case 2)
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Table 4.30: Correlation matrix for optional test score for case 3
Variables

Optional
test score 3

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Optional **
test score 3

1.000

Number of
Urologists

.036

1.000

Years of
practice

-.101

-.051

1.000

Number of
BPH patients

-.042

.128

.089

1.000

Age

-.268*

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Optional test score 3=PSA + Cystoscopy + Pressure flow + Uroflowmetry +
Intravenous pyelogram + Post voidal residual volume + others (use of these tests for
case 3)
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Table 4.31: Correlation matrix for total test score for case 1
Variables

Total
test score 1

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Total **
test score 1

1.000

Number of
Urologists

-.211*

1.000

Years of
practice

-.056

-.051

1.000

Number of
BPH patients

-.031

.128

.089

1.000

Age

.023

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Total test score 1= Medical history + DRE + Serum creatinine + Urinalysis +AUA +
PSA + Cystoscopy + Pressure flow + Uroflowmetry + Intravenous pyelogram + Post
voidal residual volume + others (use of these tests for case 1)
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Table 4.32: Correlation matrix for total test score for case 2
Variables

Total
test score 2

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Total **
test score 2

1.000

Number of
Urologists

-.259*

1.000

Years of
practice

-.066

-.051

1.000

Number of
BPH patients

-.039

.128

.089

1.000

Age

.030

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Total test score 2= Medical history + DRE + Serum creatinine + Urinalysis +AUA +
PSA + Cystoscopy + Pressure flow + Uroflowmetry + Intravenous pyelogram + Post
voidal residual volume + others (use of these tests for case 2)
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Table 4.33: Correlation matrix for total test score for case 3
Variables

Total
test score 3

Number of
urologists

Years of
practice

Number of
Age
BPH patients

Total **
test score 1

1.000

Number of
Urologists

-.030

1.000

Years of
practice

-.091

-.051

1.000

Number of
BPH patients

.008

.128

.089

1.000

Age

-.208*

-.294*

.421*

.012

1.000

*

Statistically significant (p < .05)

**Total test score 3= Medical history + DRE + Serum creatinine + Urinalysis +AUA +
PSA + Cystoscopy + Pressure flow + Uroflowmetry + Intravenous pyelogram + Post
voidal residual volume + others (use of these tests for case 3)
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blockers and TURP for case 4, alpha-blockers for case 5, and alpha-blockers and
watchful waiting for case 6. The results of this analysis are presented in Tables 4.34 to
4.41. The selection of treatment options for the three cases did not demonstrate any
significant difference based on the demographic and practice characteristics used.

Discussion for Objective Three Results
The only variables which demonstrated some effect on preferences for diagnostic
tests were age and number of urologists. Age was negatively associated with the
performance of medical history and positively associated with the performance of serum
creatinine tests. Thus, younger urologists preferred not to perform medical history and
older urologists preferred to perform serum creatinine tests more often. Also, as the
number of urologists practicing in the center increased, their preference for performance
of urinalysis and serum creatinine decreased. The analysis also revealed that as number
of urologists increases the number of recommended tests and total tests done for the case
with low and medium bothersome symptoms, decreases. Also, age was negatively
associated with the number of optional tests and total tests performed for the case with
high bothersome symptoms. This is contrary to the results of national survey of
urologists. The study with national urologists had older urologists recommending more
optional tests compared to younger urologists (Barry et al, 1997). Also, none of the
demographic and practice characteristics demonstrated any association with the
preferences for selection of treatment options. The national urologists’ study had
demonstrated a non-significant trend for younger urologists to prescribe alpha-blockers
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Table 4.34: Analysis of effect of demographic and practice characteristics on
selection of alpha- blockers for case 4 (severe)
Characteristics

Yes (%)

No (%)

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older
Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above
Number of new BPH
patients per month
>10
11-20
21-40
> 40

62.5
61.5
65.4
65.4

70.4
58.3
61.9
66.7
61.5

75.0
55.9
63.6
66.7

Test Statistics

Significance

X2 = 0.136

0.987

X2 = 0.958

0.916

X2 = 2.098

0.552

37.5
38.5
34.6
34.6

29.6
41.7
38.1
33.3
38.5

25.0
44.1
36.4
33.3

Statistically significant (p < .05)
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Table 4.35: Analysis of effect of demographic and practice characteristics on
selection of finasteride for case 4 (severe)
Characteristics

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older
Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above
Number of new BPH
patients per month
>10
11-20
21-40
> 40

Yes (%)

28.1
30.8
23.1
34.6

33.3
41.7
33.3
20.0
15.4

40.0
29.4
13.6
33.3

No (%)

Test Statistics

Significance

X2 = 0.891

0.828

X2 = 5.215

0.266

X2 = 3.919

0.270

71.9
69.2
76.9
65.4

66.7
58.3
66.7
80.0
84.6

60.0
70.6
86.4
66.7

Statistically significant (p < .05)
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Table 4.36: Analysis of effect of demographic and practice characteristics on
selection of TURP for case 4 (severe)
Characteristics

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older

Yes (%)

53.1
50.0
53.8
38.5

No (%)

Number of new BPH
patients per month
>10
11-20
21-40
> 40

37.0
62.5
38.1
46.7
53.8

35.0
50.0
54.5
45.8

Significance

X2 = 1.628

0.653

X2 = 4.513

0.341

X2 = 1.795

0.616

46.9
50.0
46.2
61.5

Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above

Test Statistics

63.0
37.5
61.9
53.3
46.2

65.0
50.0
45.5
54.2

Statistically significant (p < .05)
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Table 4.37: Analysis of effect of demographic and practice characteristics on
selection of alpha- blockers for case 5 (moderate)
Characteristics

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older
Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above
Number of new BPH
patients per month
>10
11-20
21-40
> 40

Yes (%)

90.6
88.5
88.5
92.3

92.6
95.6
76.2
86.7
88.5

85.0
97.1
81.8
91.7

No (%)

Test Statistics

Significance

X2 = 0.304

0.959

X2 = 4.887

0.299

X2 = 4.148

0.246

9.4
11.5
1.5
7.7

7.4
4.2
23.8
13.3
11.5

15.0
2.9
18.2
8.3

Statistically significant (p < .05)
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Table 4.38: Analysis of effect of demographic and practice characteristics on
selection of watchful waiting for case 6 (mild)
Characteristics

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older
Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above
Number of new BPH
patients per month
>10
11-20
21-40
> 40

Yes (%)

37.5
42.3
23.1
26.9

25.9
45.8
23.8
46.7
23.1

25.0
32.4
40.9
29.2

No (%)

Test Statistics

Significance

X2 = 0.136

0.987

X2 = 5.662

0.226

X2 = 2.913

0.405

62.5
57.7
76.9
73.1

74.1
54.2
76.2
53.3
76.9

75.0
67.6
59.1
70.8

Statistically significant (p < .05)
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Table 4.39: Analysis of effect of demographic and practice characteristics on
selection of alpha- blockers for case 6 (mild)
Characteristics

Age
>40 years
40 – 49 years
50 – 59 years
60 years or older

Yes (%)

75.0
57.7
73.1
65.4

No (%)

Number of new BPH
patients per month
>10
11-20
21-40
> 40

77.8
66.7
71.4
53.3
65.4

75.0
73.5
50.0
75.0

Significance

X2 = 2.385

0.496

X2 = 2.890

0.576

X2 = 4.780

0.189

25.0
42.3
26.9
34.6

Years of practice
at present center
> 2 years
2 – 4 years
4 – 7 years
7 – 10 years
10 years & above

Test Statistics

22.2
33.3
28.6
46.7
34.6

25.0
26.5
50.0
25.0

Statistically significant (p < .05)
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more often than older urologists and older urologists to perform TURP more often than
younger urologists. No definite explanations can be provided for this observation.

Objectives Four and Five Results
Objective four aimed to assess the level of agreement among VA urologists on the
use of diagnostic tests and procedures for patients presenting with BPH symptoms. The
null hypothesis stated no agreement among urologists for selection of diagnostic tests,
while adjusting for chance agreement.
The following procedure was followed to meet this objective. The probability
that a certain test was preferred in a particular patient, P (test) was calculated for each of
the three cases. The use of a diagnostic test in any of the cases was a dichotomous
choice, either it was preferred by the urologist or not preferred. The degree of interindividual agreement in the use of one diagnostic test in a particular case was defined as
the probability that two urologists would agree on whether or not a diagnostic test should
be used, i.e. the relative measure of agreement RMA (test) (Coughlin, Pickle, Goodman,
& Wilkens, 1992). This relative measure of agreement was obtained as follows:
RMA (test) = P(test)2 + [1-P(test)] 2
P (test) is the probability that the test was used by the urologist and 1-P(test) is the
probability that it was not used. This value varies between 0.5 and 1.0. It is a minimum
of 0.5 when P(test) is 0.5 and maximum of 1 when P(test) is either 1 or 0. The mean
RMA (test) for all the tests in a certain case were calculated and was called RMA (case).
It was used to compare the degree of agreement in the diagnostic management of the
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three cases. This was then used to calculate the generalized kappa statistic for each case
(Woolson, 1987).
KG = [RMA(case) – Pe]/(1-Pe)
Pe is the expected agreement by chance, which in this case is 0.5 as the number of
possible categories is two. The study had three cases (N) which had to be classified in
two categories by 114 (K) urologists. The variance (Woolson, 1987) for the generalized
kappa statistic in each case was obtained as follows:
σ2KG =

2
NK(K-1)

P(T)2+ P(T*)2-(2K-3)[P(T) 2+P(T*)2]+2(K-2)[P(T) 3+P(T*)3
{1-[P(T) 2 +P(T*)2]} 2

Where, P(T) is the mean value of all the P(test) for one case and P(T*) is the mean value
of not performing a test. The significance of agreement on the preference for diagnostic
tests in one case was evaluated by the Z-value obtained as follows:
Z = KG/SKG
This was done for all the three cases. The results of this analysis are summarized in Table
4.40. The kappa statistic for the case with low degree of bothersome symptoms was
0.517, was 0.529 for the case with medium degree of bothersome symptoms, and was
0.501 for the case with high degree of bothersome symptoms. The Z values for all the
three cases demonstrated significance. Thus, the null hypothesis was rejected and
conclusion drawn about VA urologists’ demonstrating significant inter-rater agreement in
their preferences for diagnostic management of BPH.
Objective five aimed to assess the level of agreement among VA urologists on the
use of treatment options for management of BPH patients. The null hypothesis for this
stated no agreement among urologists for selection of the treatment options, while
adjusting for chance agreement.
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Table 4.40: Measurement of inter-rater agreement of VA urologists in diagnostic
management of BPH
Case

kappa

SD

Z

p

Low (Case 2)

0.517

0.008

63.85

<.0001*

Medium (Case 1)

0.529

0.009

60.33

<.0001*

High (Case 3)

0.501

0.024

20.96

<.0001*

*

kappa is significantly different from zero when p <0.05
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For this, probability that a certain treatment option was preferred in a particular
patient, P(trt) was calculated for each of the three cases. The RMA(trt) was calculated
for each case in a similar manner as diagnostic tests. Similarly generalized kappa,
standard deviation and Z values were calculated for cases 4, 5 and 6. The results of this
analysis are summarized in Table 4.41. The kappa statistic for the mild case was 0.757,
was 0.806 for moderate case and 0.617 for the severe case. The Z values for all the three
cases demonstrated significance. Thus, the null hypothesis was rejected and conclusion
drawn about VA urologists’ demonstrating significant inter-rater agreement in their
preferences of treatment options for management of BPH.

Discussion for Objectives Four and Five Results
The study demonstrated significant kappa statistics among the respondents for
utilization of both diagnostic tests and treatment options. The values of kappa ranged
from 0.501 to 0.529 for diagnostic management, while for selection of treatment options
it ranged from 0.61 for the severe case to 0.80 for the moderate case. The interpretation
of kappa values is given as follows: <0 – no agreement, 0-0.19 –poor agreement, 0.20 to
0.39 -fair agreement, 0.40 to 0.59 -moderate agreement, 0.60 to 0.79 -substantial
agreement, and 0.80 to 1.00 -almost perfect agreement (Landis & Koch, 1977). Thus,
VA urologists demonstrate moderate agreement for preference of diagnostic tests, while
for preferences of therapeutic options they demonstrate substantial agreement with almost
perfect agreement for the moderate case. A study conducted by Hansen and Zdanowski
(1997), had shown different results. It showed disagreement among urologists for
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Table 4.41: Measurement of inter-rater agreement of VA urologists in management
of symptoms of BPH
Case

kappa

SD

Z

p

Mild (case 6)

0.757

0.070

10.86

<.0001*

Moderate (case 5)

0.806

0.064

12.65

<.0001*

Severe(case 4)

0.617

0.051

12.05

<.0001*

*

kappa is significantly different from zero when p <0.05
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management of men with lower urinary tract symptoms. However, that study included a
group of international urologists, a different cohort of individuals compared to this study.
Theoretically, to solve a certain problem there must be adequate information on
the basis of which decisions can be made. When different diagnostic tests are utilized
there is a likelihood that therapeutic decisions may differ as they are based on the results
of these diagnostic tests. Also, even if there is agreement about use of diagnostic tests,
there may be disagreement about the criteria for subsequent therapy. Thus, disagreement
for both diagnostic management and selection of therapy can result in higher costs for
management of a condition. However, the respondents in this study demonstrated
agreement not only for diagnostic evaluation but also for selection of therapeutic options.

Objective Six Results
This objective aimed to determine the treatment failure rate for BPH in the VA
population and the types of treatment switches commonly made following failed
initiation therapy. Section three of the questionnaire was utilized for analysis pertaining
to this objective. The survey required the respondents to recall treatments for their last
five patients, and inquired about the number from these five, who had to be switched due
to failure of initiation therapy. The type of switch made was also requested. The number
of respondents, who answered this question was 106. Thus total number of patients
whose therapy was ascertained was calculated as 106*5, i.e. 530. The total number of
switches reported was 218. This resulted in a treatment failure rate of 41.13 %. Results
of this analysis are presented in Table 4.42. A total of 26 (24.5%) urologists reported
switching 1 patient, 36 (34.0%) switching 2 patients, 26 (24.5%) switching 3 patients, 3
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Table 4.42: Estimation of treatment failure rate for BPH management among
respondents
Number of last five patients

N

Percent (%)

switched to other treatment options
None

9

7.90

1

26

24.50

2

36

34.50

3

26

24.50

4

3

2.80

5

6

5.70

Total

106

100.00

Total number of patient treated = Number of respondents answering the question * 5
= 106 * 5 = 530
Total number of patients switched = 0 (9) + 1 (26) +2 (36) + 3 (26) + 4 (12) + 5 (6) = 218

Treatment switch rate = (218/530) *100 = 41.13%
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(2.8%) switching 4 patients and 6 (5.7%) reported switching 5 patients. The remaining 9
(8.5%) respondents did not report any switches.
The most common switch reported was from alpha-blockers to surgery, with 103
(47.25%) patients being switched. The next most common switch reported was single to
combination drug therapy, done on 33 (15.14%) patients. Around 11 percent of patients
were switched from watchful waiting to drug therapy, 10 percent were switched from
combination drug therapy to surgery, 6 percent were switched from alpha-blockers to
finasteride, 3 percent were switched both from finasteride to alpha-blockers and to
surgery, and 1 percent was from watchful waiting to surgery. The remaining switches,
which were reported for less than 1 percent of patients were from one alpha blocker to a
different alpha-blocker and combination drug therapy to balloon dilation. Also, none of
the respondents reported switching patients from watchful waiting to balloon dilation,
alpha-blocker to balloon dilation, finasteride to balloon dilation and balloon dilation to
surgery (See Table 4.43) .
Additionally, analysis was conducted to determine the types of switches made
when the first line therapies were alpha-blockers, finasteride and watchful waiting. A
total of 27 (12.39 %) patients who started on watchful waiting, 115 (52.75%), who started
on alpha-blockers, and 12 (5.50%) who started on finasteride as the first line of therapy
had to be switched to other treatment options due to failure of initiation therapy. Also,
almost 89 percent of switches from watchful waiting were for drug therapy and 11
percent were for surgery. When alpha-blockers was the first line of therapy, 89.56
percent of switches made were for surgery while 10.43 percent were for finasteride. In
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Table 4.43: Summary of type of switch made for failure of initiation therapy
Type of switch

N

Alpha-blockers to surgery

103

47.25

Single to combination drug therapy

33

15.14

Watchful waiting to drug therapy

24

11.01

Combination therapy to surgery

21

9.63

Alpha-blockers to finasteride

12

5.51

Finasteride to alpha-blockers

6

2.75

Finasteride to surgery

6

2.75

Watchful waiting to surgery

3

1.38

Other (alpha to different alpha)

2

0.01

Combination drugs to balloon dilation

1

0.01

Watchful waiting to balloon dilation

0

0.00

Alpha to balloon dilation

0

0.00

Finasteride to balloon dilation

0

0.00

Balloon dilation to surgery

0

0.00

218

100.00

Total
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%

case of finasteride, 50 percent of the switches were for surgery and 50 for alpha- blockers
(see Tables 4.44 to 4.46).

Discussion for Objective Six Results
The study demonstrated an almost 42 percent treatment failure rate for initiation
therapy. Among the switches, alpha-blockers to surgery was the most common. This
could be due to the fact that a large percentage of the respondents preferred alphablockers as first line of therapy for patients with severe symptoms. The second major
switch was from single drug therapy to combination therapy. A study comparing
terazosin (an alpha-blocker), finasteride and its combination indicated that combination
therapy is no more effective than terazosin (Lepor et al, 1996). Also, there has been no
other evidence in the literature which indicates use of combination therapy to be
effective. Thus, combination therapy may result in increased use of resources, without
better outcomes. Alpha-blockers appear to be the most commonly employed first line of
therapy, but almost 53 percent of the patients had to be switched, of which almost 90
percent had to be to switched to surgery. This again substantiates the fact that surgery is
underutilized as first line of therapy for severely symptomatic BPH patients, with alphablockers being used instead. This results in a high percentage of switches from alphablockers to surgery. Almost 13 percent of the patients on watchful waiting had to be
switched, of which almost 89 percent had to be switched to drug therapy. This may be
one of the reasons why watchful waiting is an underutilized procedure with this cohort of
urologists. Switching from finasteride to another option was observed for approximately
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Table 4.44: Switching summary for watchful waiting

N

Percent (%)

27

12.39

24

88.88

Watchful waiting to surgery

3

11.12

Watchful waiting to balloon dilation

0

0.00

Total switches

Type of switch
Watchful waiting to drug therapy
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Table 4.45: Switching summary for alpha-blockers

N

Percent (%)

115

52.57

Alpha-blockers to surgery

103

89.56

Alpha-blockers to finasteride

12

10.43

0

0.00

Total switches

Type of switch

Alpha to balloon dilation
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Table 4.46: Switching summary for finasteride

N

Total switches

Percent (%)

12

5.50

Finasteride to alpha-blockers

6

50.00

Finasteride to surgery

6

50.00

Finasteride to balloon dilation

0

0.00

Type of switch
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6 percent of the patients. Thus, it appears to be a good therapeutic option with a lower
switch rate. However, it was not one of the preferred first line of therapy as observed in
the treatment options section. It was preferred more often for patients with severe
symptoms. This is consistent with the findings in literature, about finasteride being more
effective for men with larger prostates (greater than 40 grams) (Boyle, Gould &
Roehrborn, 1996). The severe case in this study included a patient with a prostate greater
than 50 grams. Additionally, finasteride has been shown to be more economical than
other treatments in men with larger prostates (Albertsen, Pellissier, Lowe, Girman, &
Roehrborn, 1999).

Objective Seven Results
This objective aimed to estimate the cost of diagnosing new BPH patients in the
VA population. For fulfillment of this objective, standard charges for all the diagnostic
tests were obtained from the VA center at West Virginia (Clarksburg). For, those
procedures which are preformed during a physician visit such as medical history, DRE
and AUA symptom index , the average urologists’ consultation fees was used. This was
obtained from the same center. All charges used are listed in Table 4.47. These charges
were utilized to compute total cost of diagnosis for each of the cases in section one of the
survey i.e. case1, 2 and 3. The physicians’ fee was taken as a base to which charges for
other tests were added depending on whether they were preferred by the urologists or not.
The mean total cost for diagnosing each case was obtained. This is summarized in Table
4.48. Thus average cost for diagnosis for the case with low symptoms was $237.37,
medium symptoms was $237.04 and high symptoms was $340.14. The charges for
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Table 4.47: Standard charges for diagnostic tests.
Tests

Charges

Recommended tests
Physicians fee {Medical history, DRE, AUA symptom index}

$80.00

Urinalysis

$4.52

Serum creatinine

$7.31

Optional tests
PSA

$26.27

Cystoscopy

$94.34

Pressure flow

$87.45

Uroflowmetry

$46.06

Intravenous pyelogram

$78.46

Post voidal residual volume

$101.72
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Table 4.48: Cost of diagnosis per patient

Case

Range ($)

Mean ($)

Low bothersome symptoms

80 – 431.37

237.04

Medium bothersome symptoms

80 – 447.67

237.37

High bothersome symptoms

80 – 526.13

340.14
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performance of the recommended tests only were calculated to be $91.83. These charges
were used to project the total costs for diagnosing new BPH patients for the VA
population. The average number of new BPH patients visiting each VAMC per month
was 36. This was multiplied by 12 to obtain the number of patients per year and by 173
to obtain the total number of new BPH patients that are expected to visit VAMCs
nationwide. Thus, the total number of new BPH patients visiting all the VAMCs
annually would be 74,736. Four cost projections were made based on four assumptions:
a) all patients visiting the centers would have low levels of bothersome symptoms, b) all
patients have medium level of symptoms c) all patients have high level of symptoms, and
d) an equal distribution of patients with low, medium and high levels of bothersome
symptoms. These assumptions were made due to the absence of any population data in
literature on distribution of the trend of bothersome symptoms. Thus, the cost of
diagnosis ranged from $17.7 million to $25.4 million depending on the assumption made.
Also, the total cost of diagnosis when only the recommended tests were used was $6.8
million (see Table 4.49).

Discussion for Objective Seven Results
The average cost of diagnosis for BPH ranged from $237.04 to $340.14 per
patient basis. Though the average number of tests for the medium case was higher than
the low case, the average cost was slightly lower. This may be due to the fact that the
respondents had demonstrated higher preference for a more expensive test like
cystoscopy for the low case compared to the medium case. On projecting these values to
the entire VA system, the cost of diagnosis ranged from $17.7 million to $25.4 million.
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Table 4.49: Cost of diagnosis for the VA

Assumed level of symptoms

Total costs

100 % Low

17,740,084.32

100 % Medium

17,715,421.44

100 % High

25,420,900.00

Equal case mix (low, medium, high)

20,292,144.34

{Recommended tests

($)

6,863,006.88}
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The total cost for the recommended tests was $6.8 million. Thus, depending on the level
of bothersome symptoms of the patient the optional tests can cost the VA $10.9 to $18.6
million. Currently, there are no empiric studies assessing the economic impact of BPH in
the U.S. or in a specific population such as VA. Totally there have been three cost of
illness studies in literature, one in UK, one in Sweden and one in New Zealand (Scott &
Scott, 1993; Drummond, Mcguire, Black, Petticrew & McPherson, 1993; Ahlstrand,
Carlsson & Jonsson, 1995). However, only one of these studies estimated the cost of
diagnosis for BPH (in New Zealand). It estimated total annual cost of diagnosis for BPH
to be 330,000 New Zealand dollars. When converted to US dollars it is equivalent
166,500 US dollars. However, investigators of this study indicated that the diagnostic
tests and procedures were under-reported and hence the cost of diagnosis may be higher.
It is important to caution readers that the charges used in this study may not include full
cost of performing tests and procedures. They may include institutional costs such as
cost of monitoring lab, cost of maintaining instruments, etc. Also, it is important to
remember that adjustment factor for locality (state to state, rural vs. urban, etc) and the
perspective used to compute costs may give different results.
This chapter presented the results of the analysis performed for accomplishing the
goals and objectives of this study and provided brief discussion of various findings. The
next chapter will provide conclusions made based on these findings and give limitations
and present implications of the study.
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CHAPTER FIVE
SUMMARY AND CONCLUSIONS

This chapter presents a review of this study, draws conclusions, provides
recommendations for future research, presents research implications and enlists
limitations of the study.
Review of the Study
Benign prostatic hyperplasia is a highly prevalent condition in elderly males
(Kirby & Christmas, 1993). In most cases it is not a fatal disease but does affect the
quality of life of patients and impacts a significant portion of the health care budget
(Baum, 1997). The VA system provides an excellent population in which this condition
can be studied, since the average age of a VA recipient is 57 years (VA fact sheet, 1998).
Guidelines have been established by AHRQ (formerly AHCPR) for the diagnostic and
therapeutic management of BPH. However, there has been little research done to study
the adherence of practitioners, including urologists, to these guidelines. Also, very little
is known about factors which affect adherence to guidelines, and inter-rater agreement on
tests used to diagnose and therapies used to manage BPH.
The goal of this study was to evaluate the diagnostic and treatment modalities for
management of BPH in the VA population. To do so, the preferences of VA urologists
were assessed to determine their adherence to guideline recommendations, effect of
demographic and practice characteristics on adherence and level of agreement among
urologists for selection of diagnostic tests and treatment options.
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Conclusions
The conclusions of the study are presented based on the objectives of the study;
Objective One: Comparison of Diagnostic Tests with Guidelines
The objective aimed to compare the preference for performance of diagnostic
tests and procedures with guidelines. The study demonstrated good adherence to
guidelines for the recommended tests and procedures. The preferences for the optional
tests varied among the respondents. The number of optional tests increased with
increasing level of bothersome symptoms. Also, the numbers of tests preferred for
diagnosis of a patient with high symptom level was significantly greater than a patient
with low or medium symptom levels.

Objective Two: Comparison of Treatment Option with Guidelines
The objective aimed to compare management of BPH symptoms with guidelines
and expert opinion. The recommended treatment strategy was watchful waiting for mild
symptoms, drug therapy for moderate symptoms and TURP for severe symptoms.
However, the respondents preferred the use of alpha-blockers for all the cases,
irrespective of the symptom severity. In other words, alpha-blockers are being
recommended when pharmacological therapy is not required and also when surgery is a
better alternative for managing the symptoms. Thus, it appears that VA urologists do not
conform too well with guidelines and expert opinion in their preferences for therapeutic
management of BPH symptoms.
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Objective Three: Effect of Demographic and Practice Characteristics on Preferences
This objective aimed to assess the effect of demographic and practice
characteristics on preferences of urologists for diagnostic procedures and selection of
treatment options. Age and number of urologists were the only two variables which
demonstrated some effect on preference for diagnostic tests. Age was negatively
associated with the performance of medical history and positively associated with the
performance of serum creatinine tests. Thus, we can conclude that younger urologists
preferred not to perform medical history and older urologists preferred to perform serum
creatinine tests more often. Also, as the number of urologists practicing in the center
increased, their preference for performance of urinalysis and serum creatinine decreased.
The analysis also revealed that as number of urologists increases the number of
recommended tests and total tests done for the case with low and medium bothersome
symptoms, decreases. Also, age was negatively associated with the number of optional
tests and total tests performed for the case with high bothersome symptoms. However,
the correlation coefficient for all these observations was less than 0.3. Also, none of the
demographic and practice characteristics demonstrated any association with the
preferences for selection of treatment options. Thus, no valid conclusions can be made
from the study about the effect of demographic and practice characteristics on
respondents’ preferences.

Objectives Four and Five: Estimation of Levels of Agreement Among Respondents
These objectives were designed to measure the level of agreement among VA
urologists for assessment and management of BPH symptoms. The VA urologists
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demonstrate moderate agreement for preference of diagnostic tests, while for preferences
of therapeutic options they demonstrate substantial agreement to almost perfect
agreement depending upon the severity of the patient case.

Objective Six: Estimation of Failure of Initiation Therapy
The objective aimed to assess treatment failure rate and determine the common
switches employed for failed initiation therapy. The study demonstrated an almost 42
percent treatment failure rate for initiation therapy. Among the types of switches, alphablockers to surgery was most common. The second major switch was from single drug
therapy to combination drug therapy. Also, among the therapeutic options, alpha-blockers
demonstrated the highest switch rate followed by watchful waiting and finasteride.

Objective Seven: Estimation of Cost of Diagnosis
The objective aimed to estimate cost of diagnosis for BPH based on the
preferences of the VA urologists. The cost of diagnosis per patient ranged from $237.04
to $340.14 depending on the level of bothersome symptoms. Also, the total projected
cost of diagnosis for BPH for all the VAMCs ranged from 17.7 million dollars to 25.4
million dollars.

Directions for Future Research
This study can serve as a springboard for several future studies on management of
BPH. First, adherence to guidelines needs to be assessed by tracking BPH patients in the
VA data to determine the diagnostic and treatment options undertaken. This would help
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validate the results of this study and also control for the effect of patient characteristics
such as age, co-morbidities, etc.
With the emergence of managed care, the role of primary providers in managing
BPH has been increasing. Thus, comparing the practice patterns of primary care
providers with the guidelines would make another interesting study. Also, management
of BPH in other health care settings, like Medicaid, Medicare (includes individuals over
the age of 65) needs to be studied. These programs have a tremendous impact on the
U.S. health care system. Hence appropriate management of this condition in these health
systems is important.
Kortt and Bootman (1996) reviewed the literature to identify and evaluate studies
that had addressed the economic burden of BPH or costs associated with alternative BPH
therapies. This search yielded only 14 research studies associated with some economic
analysis of BPH or therapies used in its management, of which only 2 studies performed
a cost of illness evaluation. Both these have been conducted in countries outside the U.S.
i.e. New Zealand and United Kingdom. Subsequent to Kortt and Bootman’s literature
review only one additional study was found in literature, and this was also conducted
outside the U. S. (in Sweden). Thus, there is a need to assess economic impact of BPH in
the U.S. or in a specific population such as the VA, Medicaid, or Medicare.
Finally, there is a need to study patient outcomes associated with BPH. This may
include quality of life assessments of patients with BPH, estimation of indirect costs and
pharmacoeconomic studies comparing various drug therapy and surgical options
currently used to treat this disease.
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Research Implications
This study was undertaken to evaluate the diagnostic and treatment modalities in
the management of BPH in the Veterans Administration population. To do so,
preferences of the VA urologists were compared with published clinical guidelines. The
findings of this study should be useful to the Veterans Administration program in their
effort to encourage appropriate practice patterns and thereby produce better patient
outcomes. The study also has implications for patients and policy makers. These
implications are described in the following sections.

Implications to the Veterans Administration Program
The results of this study demonstrated that VA urologists showed good adherence
to practice guidelines for diagnosis of BPH. However, the same is not true for treatment
strategies. They prefer use of alpha-blockers for management of symptoms, regardless of
symptom severity. This may not be the most appropriate way of managing this condition,
since it has high economic implications. Also, the study demonstrated substantial to
almost perfect agreement for selection of treatment options to manage BPH. Hence,
there is a need to validate study results by following BPH patients or by tracking them in
the VA database. If similar results are obtained one can conclude that VA urologists’
practice patterns are not consistent with clinical guidelines. Thus, there may be a need to
increase awareness among urologists for appropriate use of therapeutic options.
Prescribing pharmacological therapy for patients who do not require active treatment or
require surgical intervention may lead to increased expenditures. The VA program can
develop and implement educational programs to increase the use of watchful waiting and
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TURP for patients with mild and severe symptoms, respectively. This could result in
better use of resources through avoidance of unnecessary procedures and therapeutic
options. Additionally, appropriate management of BPH would result in better patient
outcomes, as this would result in better quality of care, fewer switches in therapeutic
options, better control of symptoms and improvement in quality of life of patients.

Implications to Patients
The findings of the study are also relevant for patients. BPH is a condition that
affects quality of life. Inappropriate diagnosis and treatment patterns would only
exacerbate the quality of life of BPH patients. Hence, study results could aid in
encouraging urologists to adhere to appropriate practice patterns. Since the guidelines
were established to provide optimum outcomes, adhering to them will provide better
relief of symptoms and thus improve quality of life of BPH patients.

Implications to Policy Makers
The guidelines were established by the AHRQ (AHCPR) in 1994. The guidelines
did not include specific treatment recommendations for the management of BPH patients
with moderate and severe symptoms. This makes it difficult to assess appropriate
practice patterns for such cases. Also, newer non-invasive therapies like TUNA, TUMT,
stents, etc. have been emerging in recent times. These were not part of the guidelines due
to lack of data on their effectiveness. Thus, there may be a need to re-visit the guidelines
so as to make them more effective and contemporary.
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Study Limitations
The study included a sample of 292 urologists practicing in the VA population.
Of these, 114 urologists responded to the survey. Of the 22 VISNs, 21 were represented
in the study. Also, urologists from 42 states were represented among the respondents.
Thus, there appeared to be an adequate representation of the population. The nonresponse bias analysis demonstrated no significant difference between respondents and
non-respondents for demographic and practice characteristics. However, it did
demonstrate difference in urologists’ preferences for the utilization of five of the
diagnostic tests compared to respondents. Thus, non-response bias limits the
generalizability of the study results to the entire VA urologist population.
Another limitation of the study was the use of simulated patients. It can be argued
that a simulated patient does not adequately represent a real patient in clinical practice.
However, the information from each patient is reproducible and ensures that every doctor
obtains the same information from each patient. Thus, the method should be regarded as
an instrument with which the preferences of the urologists can be analyzed. Another
argument is the selection of cases for the instrument. Since BPH is a common condition
among elderly males, it is likely to co-exist with other health-related problems. However,
the cases selected in the instrument did not include any other health-related problems, (or
co-morbidities) which an elderly male may have. Since the utilization of diagnostic
procedures and therapeutic options may be influenced by co-morbidities, the cases in the
instrument used in the study may not be most representative of the patient population.
In addition to the above limitations, the study also suffers from another drawbackthe absence of patient preferences. The guidelines for BPH management stress the
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importance of patient preferences. It is reasonable to believe that patients’ preferences
would strongly influence management of the condition. However, time and budget
constraints did not permit exploration of this aspect.
Finally, the limitations of using a self-administered mail questionnaire for
collection of data would apply for this study. Although mail questionnaire possess the
advantages of being relatively inexpensive to administer, provides larger possible
samples, offers greater assurance of anonymity, ensures standardized wording and
elimination of interviewer bias, there are substantial limitations to use of selfadministered questionnaires. Measurement errors could have occurred and may have
caused: (1) the respondent failing to understand the instructions or items; (2) the
respondent answering in a way he/she thinks is desirable to the researcher; and (3) the
intended person not completing the questionnaire.
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APPENDICES
Appendix A: Veterans Integrated Service Networks
VISN1: VA New England Healthcare System
VISN2: VA Healthcare Network Upstate New York
VISN3: Veterans Integrated Service Network
VISN4: VA Stars and Stripes Healthcare Network
VISN5: VA Capitol Network
VISN6: The Mid-Atlantic Network
VISN7: The Atlanta Network
VISN8: VA Sunshine Healthcare Network
VISN9: Mid South Veterans Healthcare Network
VISN10: VA Healthcare System of Ohio
VISN11: Veterans Integrated Service Network
VISN12: The Great Lakes Health Care System 13
VISN13: VA Upper Midwest Health Care Network
VISN14: Central Plains Network
VISN15: VA Heartland Network
VISN16: Veterans Integrated Service Network
VISN17: VA Heart of Texas Health Care Network
VISN18: Southwest Network
VISN19: Rocky Mountain Network
VISN20: Northwest Network
VISN21: Sierra Pacific Network
VISN22: Desert Pacific Healthcare Network
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Appendix B: AHRQ Decision Diagram

Initial Evaluation
History
Physical examination and
DRE
Urinalysis
Creatinine
PSA (optional)

•
•
•
•
•

Presence of Refractory retention
Any of the following, clearly secondary to
BPH:
• Recurrent urinary tract infection
• Recurrent or persistent gross hematuria
• Bladder stones
• Renal insufficiency

Surgery
Quantitative symptom assessment

Mild

Moderate to severe
Optional diagnostic tests based on physician
and patient preferences

Offer treatment alternatives
•
•
•

Watchful
waiting

Surgery:
TUIP, TURP,
open

Balloon
dilation

Flowrate
Residual urine
Pressure flow

Medical
Therapy
Yes

Option for urethroscopy or sonography if
important in planning operative approach

Compatible
with
obstruction?
No

Non-BPH problem
identified and
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Appendix C: American Urological Association Symptom Index for Benign Prostatic
Hyperplasia
Less
Than
Half
the
Time

About
Half
the
Time

More
Than
Half
the
Time

Almost
Always

Not at
All

Less
Than 20%
of the
Time

1. Over the past month or so, how often
have you had a sensation of not
emptying your bladder completely after
you finished urinating?

O

O

O

O

O

O

2. Over the past month or so, how often
have you had to urinate again less than
2 hours after you have finished?

O

O

O

O

O

O

3. Over the past month or so, how often
have you found you stopped and started
several times when you urinated?

O

O

O

O

O

O

4. Over the past month or so, how often
have you found it difficult to postpone
urination?

O

O

O

O

O

O

5. Over the past month or so, how often
have you had a weak urinary stream?

O

O

O

O

O

O

6. Over the past month or so, how often
have you had to push or strain to begin
urination?

O

O

O

O

O

O

7. Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until you got up in the
morning?
O None

O Once

O Twice

O 3 Times
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O 4 Times

O 5 Times or more

Appendix D: Survey Instrument
UROLOGISTS’ PREFERENCES IN THE MANAGEMENT OF
BENIGN POSTATIC HYPERPLASIA (BPH)
SECTION I
The following section is designed to determine your preferences for the diagnostic tests
and procedures commonly used by you in diagnosing BPH in your patients. For each of
the following patient profiles indicate the diagnostic tests you would have performed on
the patient (check all that apply).
Patient Number 1: B.T., a 66-year-old white male comes to your clinic with bothersome
urinary symptoms. He complains of increased frequency, incomplete bladder emptying
and occasional burning sensation. He denies any hematuria. He also reports occasional
post void dribbling and nocturia of about 3-4 times a night.
Medical History
Digital Rectal Exam
Urinalysis
Serum Creatinine
PSA
.
AUA Symptom Score

 Cystoscopy
Pressure Flow
Uroflowmetry
Intravenous Pyelogram
Post Void Residual Volume
Other (please describe)_______
 __________________________

Patient Number 2: J.J., a 54-year-old African-American man, presents to your office
with lower abdominal discomfort. He reports occasional difficulty initiating urination,
midstream stoppage and post void dribbling. He also complains of nocturia of about 2
times a night.
Medical History
Digital Rectal Exam
Urinalysis
Serum Creatinine
PSA
.
AUA Symptom Score

 Cystoscopy
Pressure Flow
Uroflowmetry
Intravenous Pyelogram
Post Void Residual Volume
Other (please describe)_______
 _________________________

Patient Number 3: M.J., a 72-year-old white man presents to you with history of blood
in the urine. He gives also a history of increasing difficulty initiating urination, frequent
midstream stoppage, frequent burning on urination, and post void dribbling. He also
reports a decrease in the force and caliber of his urinary stream as well as incomplete
bladder emptying and complains of nocturia of more than 4 times/night and daytime
frequency of more than 10 times/day.
Medical History
Digital Rectal Exam
Urinalysis
Serum Creatinine
PSA
.
AUA Symptom Score
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 Cystoscopy
Pressure Flow
Uroflowmetry
Intravenous Pyelogram
Post Void Residual Volume
Other (please describe)_______
____________________________

SECTION II
Now, we would like to know your preferences with regard to treating or managing BPH
in your patients. Again for each of the following patient profiles indicate the treatment
you would prefer to initiate.
Patient Number 4: A.D., a 75-year-old African-American male comes with the problem
of urinary incontinence. He also gives a history of difficulty initiating urination,
midstream stoppage and terminal dribbling. Rectal examination reveals an enlarged
prostate of 50-55 gms. A.D. gives a history of nocturia approximately 4-5 times a night,
daytime urinary frequency of 8-10 times a day and he reports of blood in urine.
Laboratory findings are as follows: PSA -4.1, AUA ss -28, serum creatinine -1.2, residual
volume -300ml, flow rate -7ml/sec.
Watchful Waiting
Alpha Blockers
 Finasteride
Balloon Dilation
 TURP

 TUIP

Open Prostactomy

 Laser Prostactomy
 TUVP

 Other_________________

Patient Number 5: R.C., a 68-year-old Hispanic man, comes to your clinic with severe
abdominal discomfort. He reports a history of increased difficulty initiating urination,
midstream stoppage and terminal dribbling. R.C. complains of nocturia of 3-4
times/night. DRE reveals an enlarged prostate of approximately 25-30 gms and firm.
Laboratory findings are as follow:
PSA-2.8, AUA ss - 15, serum creatinine -0.8, residual volume -150ml, flow rate 13ml/sec.
Watchful Waiting
Alpha Blockers
 Finasteride
Balloon Dilation
 TURP

 TUIP

Open Prostactomy

 Laser Prostactomy
 TUVP

 Other_________________

Patient Number 6: G.M., a 60-year-old male, presents to your clinic with lower
abdominal discomfort. He gives a history of increased difficulty initiating urination, a
significant decrease in the force of his urinary stream, occasional midstream stoppage,
and post void dribbling. Upon digital rectal examination, the prostate is 20-25 gms and
benign. Laboratory findings are as follows: PSA -1.2, AUA ss-6, serum creatinine -0.5,
flow rate -20 ml/sec, residual volume -80ml.
Watchful Waiting
Alpha Blockers
 Finasteride
Balloon Dilation
 TURP


 TUIP

Open Prostactomy

 Laser Prostactomy
 TUVP

 Other_________________
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SECTION III
Often times therapy initiated for managing BPH does not improve the symptoms of BPH.
In such situations it becomes necessary to select or switch other treatment options. We
would like to know how often it has become necessary for you to move to another
treatment option during management of BPH in your patients.
Think of the last five (5) patients of yours that were diagnosed with having BPH. Please
indicate for how many of these five patients you found it necessary to switch to another
treatment option.
All 5

4

3

2

1

none

If you have marked “none” above please move on to Section IV.
For the patients for whom you switched or selected another therapy option (as indicated
above) please indicate the type of switch that was made.
# of patients
watchful waiting to drug therapy
watchful waiting to balloon dilation
watchful waiting to surgery
alpha blockers to finasteride
alpha blockers to balloon dilation
alpha blockers to surgery
finasteride to alpha blockers
finasteride to balloon dilation
finasteride to surgery
single drug therapy to combination therapy
combination therapy to balloon dilation
combination therapy to surgery
balloon dilation to surgery

____
____
____
____
____
____
____
____
____
____
____
____
____
Total
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____ (should equal the
number circled above)

SECTION IV
Finally, a few questions about you and your VAMC:
Yes

1. Does your VAMC have a formulary?

No

2. If yes to Q1, then which of the following drugs are on the formulary?
Terazosin

Doxazosin

3. Your VAMC is located in :

Prazosin

State ___________

Finasteride
Town ____________

4. Number of urologists practicing at your VAMC: ___________________
5. Years of practice for you at current VAMC:

_____ years

____ months

6. Number of new BPH patients visiting your center per month are: _________________
7. Your age: Less than 40
8. Your gender:

Male

40-49

50-59

60 or older

Female

COMMENTS:
Is there anything else you would like to tell us about your preferences or experiences with
managing BPH? If so, please use this space to provide your comments.

THANKYOU
Please return the completed survey in the enclosed business reply envelope.
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Appendix E: Cover Letter for First Mailing
December 10, 1999
Dear Urologist:
As you may be aware, in the U.S., more than 1 million men present annually with
symptoms associated with benign prostatic hyperplasia (BPH). The quality of life of BPH
patients can decline significantly since symptoms may interrupt normal daytime activities
or sleep, create anxiety, or reduce perception of general health. The median age of 57
years in the Veterans Administration (VA) population makes BPH a common condition
among men in this population. With an increase in life expectancy, the cases of BPH
among this population are expected to continue to increase.
There are several diagnostic tests and treatment options available for the management of
BPH. We at West Virginia University School of Pharmacy are interested in determining
the preferences of urologists in the management of BPH. Your name was randomly
selected from a national list of urologists serving the VA population as someone who
could provide valuable information. We would appreciate it if you could take a few
minutes to complete the enclosed survey.
Your participation in this study is voluntary. You do not need to answer all questions
even though we would prefer that you do. However, since this survey is part of a
Master’s thesis project, complete responses are vital for the study results to be
meaningful. We are interested in your opinion, and you may be assured of complete
confidentiality. Your individual responses to this survey will be known only to
researchers at West Virginia University. The survey has been coded only for follow-up
purposes.
As our way of saying thank you for participating in this study, you may also enter your
name in a raffle drawing. One prize of $100, one of $75 and two of $50 will be awarded
to four individuals whose names will be randomly drawn from the raffle tickets received.
If you are the lucky winner of any of these prizes you will be notified. For this purpose,
we would appreciate it if you would provide your name, telephone number and address
on the raffle ticket provided. You may return this ticket with the completed survey.
Kindly return the completed questionnaire in the enclosed, postage-paid envelope. Thank
you very much for your time, effort and promptness in providing this valuable
information. If you have any questions, please do not hesitate to call us at (304) 2936991 (or 0228).
Sincerely,
Ancilla Fernandes
Graduate Student

Mayur M. Amonkar, Ph.D.
Assistant Professor (Pharmacy)

Unyime O. Nseyo, M.D.
Professor (Urology)

Suresh Madhavan, MBA, Ph.D.
Associate Professor (Pharmacy )
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Appendix F: Cover Letter for Second Mailing
January 20, 2000
Dear Dr. “Name of the Urologists”
Several weeks ago, a questionnaire regarding your preferences in the management of
benign prostatic hyperplasia was sent to you. I realize that you have been very busy.
However, I would personally like to request your help in completing the questionnaire for
this important clinical study. If you have responded, please disregard this letter and
accept our gratitude for time and effort.
Your participation in this study is voluntary. You do not need to answer all questions.
However since this survey is part of a Master’s thesis project, complete responses are
vital for the studies results to be meaningful. I am interested only in your opinion, and
you may be assured of complete confidentiality. Only researchers at West Virginia
University will know your individual responses to this survey and all the analysis will be
done in aggregate form.
As a way of saying thank you for participating in this study, you may also enter your
name in a raffle drawing. One prize of $100, one of $75 and two of $50 will be awarded
to four individuals whose names will be randomly drawn from the raffle tickets received.
If you are the lucky winner of any of these prizes you will be notified. For this purpose,
please provide your name, telephone number, and address on the raffle ticket provided
and return this ticket with the completed survey.
Kindly return the completed questionnaire in the enclosed, postage-paid envelope. Thank
you very much for your time, effort and promptness in providing this valuable
information. If you have any questions do not hesitate to call me at (304) 293-6991.
Sincerely,

Ancilla Fernandes,
Graduate student.
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Appendix G: Non-response Survey
BENIGN PROSTATIC HYPERPLASIA MANAGEMENT SURVEY
Q1. Mentioned below are some of the possible reasons that might have prevented you from responding to
the "Urologists' Preferences in the Management of Benign Prostatic Hyperplasia (BPH)" survey sent to you
earlier. Please check the one that most applies to you.

did not have enough time to complete the survey
 forgot about the survey
 survey was misplaced
 did not have enough incentive to
complete the survey
 not interested in such studies
 other _____________________________

did not receive the survey at all
 survey was too long
 don't like to respond to surveys
 do not have enough information a
about benefits of the study
 topic was irrelevant

Q2. For the following patient profile indicate the diagnostic test(s) you would have performed on the
patient (check all that apply):
M.J., a 72-year-old white man presents to you with history of blood in the urine. He also gives a
history of increasing difficulty initiating urination, frequent midstream stoppage, frequent burning on
urination, and post void dribbling. He also reports a decrease in the force and caliber of his urinary
stream as well as incomplete bladder emptying and complains of nocturne of more than 4 times/night
and daytime frequency of more than 10 times/day.















Medical History
Digital Rectal Exam
Urinalysis
Serum Creatinine
PSA
.
AUA Symptom Score

Cystoscopy
Pressure Flow
Uroflowmetry
Intravenous Pyelogram
Post Void Residual Volume
Other (please describe) _____________

Q3. A few questions about yourself...
Does your VAMC have a formulary?





Yes

Your VAMC is located in : State ___________

No

Town ____________

Number of urologists practicing at your VAMC: ___________________
Years of practice for you at current VAMC:

_______ years

______ months

Number of new BPH patients visiting your center per month are: ______
Your age:



Your gender:

Less than 40



Male





40-49
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Female

50-59



60 or older

Appendix H: Cover Letter for Non-response Survey
February 27, 2000

Dear Urologist,
During the past two months you may have received two mailings of a questionnaire
regarding your preferences in the management of benign prostatic hyperplasia. I realize
that you have been very busy and have chosen not to answer or were not able to answer.
We would appreciate it if you could please take a couple of minutes to answer a few
questions on the attached sheet.
All responses will be kept completely confidential. Please complete and return it, in the
enclosed postage-paid envelope at your earliest convenience. If you have already
responded to the previous questionnaire, please disregard this letter and accept our
gratitude for your time and effort. If you have any questions, please do not hesitate to
call us at (304) 293-6991
Sincerely,

Ancilla Fernandes
Graduate student
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